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1 SUMMARY 
Huntington’s Disease is a neurodegenerative disorder characterized by motor dysfunction, 
emotional disturbance, dementia and weight loss. The disorder is caused by an autosomal 
dominant expansion of a CAG repeat encoding for a polyglutamine stretch in exon 1 of the 
huntingtin gene. Mutated huntingtin gains a neurotoxic function, leading to the onset of 
clinical symptoms mostly in mid-life. The progression of Huntington’s Disease is 
characterized by a marked degeneration of gray and white brain matter. A loss of vulnerable 
neurons, most notably striatal medium-sized spiny neurons, is observed, while resistant 
populations are spared. No cure for Huntington’s Disease exists and the disorder progresses 
relentlessly with a lethal outcome about two decades after diagnosis.  
In my thesis I explored four main projects. As the reported cellular dysfunctions in 
Huntington’s Disease are numerous, I generated an inducible, neuronal model to investigate 
the effects of mutant huntingtin expression at the cellular level (Chapter 4.1). This inducible 
model allowed for adjustable expression levels of different wild-type and mutant huntingtin 
fragments in proliferating or differentiated HN10 neuroblastoma cells, thus providing the 
ability to examine huntingtin protein effects under different cellular conditions. I was able to 
show that this model displays key major characteristics found in Huntington’s Disease 
patients like transcriptional dysregulation, mutant huntingtin aggregation and decrease in cell 
viability. Subsequently, I made use of this newly designed cellular model to develop 
huntingtin detection methods to further investigate the biological role of soluble or aggregated 
mutant huntingtin for Huntington’s Disease development and progression. 
Since the role of huntingtin aggregate formation in Huntington’s Disease is still under debate, 
I designed a simple method based on agarose gel electrophoresis for qualitative and 
quantitative characterization of huntingtin aggregates in my second project. Using this method, 
I proceeded to analyze samples of cellular and animal Huntington’s Disease models and was 
able to show that in the brain of transgenic R6/2 mice aggregates became larger as a function 
of age and disease progression. Importantly, I showed that in primary striatal neurons and in 
brains of two Huntington’s Disease mouse models (transgenic R6/2 and HdhQ150 knock-in 
mice), aggregate formation preceded detection of any functional deficits, supporting the 
theory that aggregates play an important pathogenic role in Huntington’s Disease (Chapter 
4.2). 
In the third project, I developed a method for the detection of intracellular mutant huntingtin, 
the causative agent of Huntington’s Disease. I generated a small recombinant protein tag 
which is recognized by a pair of readily available, high affinity monoclonal antibodies, thus 
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making this method generally applicable for detection of other recombinant proteins. Using 
this tag I was able to establish a time resolved fluorescence resonance energy transfer (time 
resolved FRET) based assay which allows for rapid, sensitive and robust detection of cellular 
mutant huntingtin levels. I miniaturized this assay to a homogeneous 1536 well microplate 
format and demonstrated that the assay system is suitable for the identification of  compounds 
that increase or decrease the levels of huntingtin protein (Chapter 4.3). 
In the fourth project, by using antibodies specific against endogenous huntingtin epitopes, I 
expanded this time resolved FRET detection method to monitor the levels of endogenous 
soluble mutant huntingtin in cellular, animal and human samples. I showed that the soluble 
mutant huntingtin levels inversely correlate with the amount of mutant huntingtin aggregates 
in the brains of aging R6/2 mice. Importantly, I was able to quantify mutant huntingtin 
concentrations in blood fractions from Huntington’s Disease patients, providing for the first 
time a bioassay to assess the relevance of mutant huntingtin levels as a marker for disease 
progression. This biomarker could help to monitor the efficacy of drug treatments aimed at 
lowering mutant huntingtin levels in preclinical and clinical trials (Chapter 4.4). 
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2 INTRODUCTION 
2.1 Huntington’s Disease  
Huntington’s Disease, also sometimes referred to as Huntington’s Chorea, is the most 
common autosomal-dominant neurodegenerative disorder with a prevalence of 5 to 8 cases 
per 100’000. Disease symptoms include severe motor dysfunctions (chorea), psychiatric 
alterations and progressive dementia with onset normally in middle-age. The solitary cause for 
Huntington’s Disease is an elongation of a polyglutamine repeat at the amino terminus of the 
ubiquitously expressed huntingtin protein. The underlying pathophysiological mechanisms of 
mutant huntingtin are yet to be elucidated. Currently, aside from limited symptomatic 
treatments against emotional disturbances or chorea, no effective treatment for Huntington’s 
Disease which can prolong the life expectancy of patients or stop their cognitive decline exist.  
 
2.1.1 History 
The term “chorea” for the classification of movement 
disorders has been first used by Paracelsus, professor of 
medicine at the university of Basel in the 16th century 
(Paracelsus, 1527). First records with reports of chronic 
choreas, today accepted to describe Huntington’s Disease 
patients, were published in the middle of the 19th century 
(Dunglison, 1848; Lund, 1860; Waters, 1842). The 
eponymous publication which described in detail not only 
the choreic movements but also the progressive dementia 
as well as the clear hereditary nature of the disease was 
published by George Huntington in 1872 (Huntington, 
1872), (Figure 1). Huntington’s Disease rose to public attention in 1952 when the American 
folk singer Woody Guthrie was diagnosed with the disease. His death in 1967 prompted the 
foundation of the Committee to Combat Huntington’s Disease, one of the first patient support 
groups that greatly increased fund-raising for research and public awareness of the disease. 
The improved conditions for Huntington’s Disease research were reflected in the research 
milestones over the next decades. In 1983, the chromosomal localization of the disease was 
discovered (Gusella et al., 1983) and in 1993 the gene responsible for Huntington’s Disease 
was isolated and characterized (Group, 1993a). Since then, research progress has included the 
design of the first animal model (Mangiarini et al., 1996), the discovery of intracellular 
huntingtin aggregates (Davies et al., 1997) and several hypothesis for toxic mechanisms of 
Figure 1: George Huntington. 
Reproduced from the “Huntington 
number” of Neurographs (1908). 
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action were put forward (Bates, 2003). However, despite of this remarkable progress, no 
treatment tackling the underlying mechanisms of action causing Huntington’s Disease is 
available today. 
 
2.1.2 Clinical manifestations of Huntington’s Disease 
Even though the sole cause of Huntington’s Disease in every patient is a single mutational 
event causing a CAG trinucleotide expansion in the huntingtin gene, the clinical 
manifestations are found to be diverse and can be mistaken for other neurodegenerative 
diseases like Huntington’s Disease-like 2 (Greenstein et al., 2007; Margolis et al., 2004; 
Rudnicki et al., 2008; Walker et al., 2003) or dentatorubropallidoluysian atrophy (Nakano et 
al., 1985). In addition, even though symptom onset mostly occurs between 30 to 50 years of 
age, juvenile and late-onset cases are frequent, widening the possible range of symptom onset 
to 2-85 years of age (Hayden et al., 1987; Osborne et al., 1982). Approximately 44-72% of 
these variations in age of onset can be explained by the length of the CAG repeat, making the 
trinucleotide and the resulting polyglutamine repeat length in the huntingtin protein the most 
important determinant for the age of onset (Myers, 2004; Wexler et al., 2004). Because of the 
wide variety in symptoms and ages of onset, misdiagnoses based on clinical symptoms used 
to occur regularly (Bateman et al., 1992; Folstein et al., 1986) and molecular testing for CAG 
repeat length became key for precise diagnosis of Huntington’s Disease (Kremer et al., 1994).  
Since molecular testing will be performed only in patients suspected to show clinical 
symptoms of Huntington’s Disease or patients known to be at risk because of their family 
history, it is important to note that no singular symptomatic finding is sufficient for a clinical 
diagnosis. In the early disease stages, minor alterations in intellectual capacity, increased 
anxiety and personality changes are observed (Kirkwood et al., 2000; Kirkwood et al., 2001; 
Penney et al., 1990) although these changes are often attributed retrospectively after a more 
certain diagnosis based on more profound symptoms or molecular testing.  
The classical phenotype in the mid-course of Huntington’s Disease progression is 
characterized by motor abnormalities. The motor impairments include chorea (rapid, random 
and uncontrollable movements (Dunglison, 1848; Huntington, 1872; Lang, 1989; Lund, 1860; 
Penney et al., 1990; Waters, 1842; Young et al., 1986)), bradykinesia (decrease of movement 
speed (Thompson et al., 1988)) and dystonia (abnormal movements with increased muscle 
tone (Andrich et al., 2007; Bittenbender and Quadfasel, 1962)). Even though chorea is by far 
the most prominent clinical manifestation found in over 90% of all Huntington’s Disease 
patients, it is a poor marker for disease progression as chorea intensity tends to change in a 
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non-predictable manner from patient to patient and is often replaced in later stages of the 
disease by other motor impairments such as dystonia (Mahant et al., 2003; Young et al., 1986).  
In advanced stages of Huntington’s Disease, independent living becomes impossible for the 
patients due to severe motor impairment and increased cognitive decline (Nance and Sanders, 
1996). These later disease stages are often accompanied by increased sleep disturbances 
(Hansotia et al., 1985; Silvestri et al., 1995) and weight loss (Morales et al., 1989; Sanberg et 
al., 1981). Patients die prematurely of complications associated with the disease such as 
pneumonia or dysphagia (Lanska et al., 1988a; Lanska et al., 1988b) with the median duration 
between onset of symptoms and time of death being 15 to 20 years (Foroud et al., 1999). 
 
2.1.3 Neuropathology of Huntington’s Disease 
In the past, asymptomatic and early symptomatic disease stages were thought not to be 
accompanied by distinct neuropathological changes. However, more recent studies were able 
to show alterations in cytoskeletal proteins in cortical neurons even at these early 
presymptomatic timepoints (DiProspero et al., 2004; Modregger et al., 2002). Futhermore, 
advances in MRI imaging allowed to 
visualize cortical thinning and atrophy in 
presymptomatic mutation carriers, providing 
a possible neurological explanation for the 
very early psychiatric alterations (Kassubek 
et al., 2004; Peinemann et al., 2005; Rosas et 
al., 2001; Rosas et al., 2006). 
Brains from patients with advanced stages of 
Huntington’s Disease show a general atrophy 
with weight reduction of about 10 to 20% 
(Figure 2). Affected brain areas with 
distinctive neuronal loss include the 
hippocampus, cortical layers 3, 5 and 6, Purkinje cells of the cerebellum, tuberal nuclei of the 
hypothalamus as well as the centromedial-parafascicular complex of the thalamus (Bates et al., 
2002; Jeste et al., 1984; Kremer et al., 1991; Spargo et al., 1993). Despite this widespread 
neuronal loss, neurodegeneration in Huntington’s Disease is still considered to be remarkably 
selective because of the strikingly severe and distinct atrophy in the most affected brain region, 
the striatum (Bruyn, 1979; Roos et al., 1985; Vonsattel et al., 1985). In this area almost all of 
the medium-sized spiny striatal neurons are lost in the later stages of the disease, while large 
Figure 2: Comparison of normal brain (right) to a 
brain of a late stage Huntington's Disease patients 
(left). General atrophy of the Huntington brain is 
visible in all brain areas with most severe atrophy 
apparent in the striatum. Photo courtesy of the 
Harvard Brain Tissue Resource Center. 
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striatal neurons, aspiny interneurons and striatal astrocytes are relatively resistant to 
Huntington’s Disease related degeneration (Cicchetti et al., 2000; Ferrante et al., 1987a; 
Ferrante et al., 1987b). The striatum itself comprises the caudate nucleus and putamen and 
interconnects to subcortical nuclei (such as globus pallidus, subthalamic nucleus and 
substantia nigra) which influence movement, motivation and reward behavior through 
modulation of higher brain areas (Alexander, 1994; Alexander and Crutcher, 1990; Hoover 
and Strick, 1999). In healthy individuals, the medium-sized striatal neurons send inhibitory 
signals to the external and internal segments of the globus pallidus as well as to the substantia 
nigra pars reticulata, (Figure 3, left side). 
 
Cerebral cortex
Striatum
GPe
STN GPi/SNr
SNc
Thalamus
Cerebral cortex
Striatum
GPe
STN GPi/SNr
SNc
Thalamus
Healthy Brain Huntington‘s Disease Brain
Basal Ganglia Basal Ganglia
 
Figure 3: Basal Ganglia pathways in healthy and Huntington’s Disease brain, simplified schematic view, 
modified from Bates et al., 2002. Brain regions of the basal ganglia encircled in grey. The striatum, the most 
severely affected brain region in Huntington’s Disease is depicted in yellow. Widespread neurodegeneration in 
the striatum causes a decrease of its inhibitory function in the basal ganglia pathway. This results in decreased 
activation of the basal ganglia output regions (GPi/SNr) which have an inhibitory effect on thalamic nuclei. 
Therefore, subsequent increased excitation of the thalamus due to lacking inhibitory input from the basal ganglia 
occurs and are thought to be the cause for the uncontrolled movement and psychiatric alterations seen in 
Huntington’s Disease patients. GPe: Globus pallidus external segment; GPi: Globus pallidus internal segment; 
STN: Subthalamic nucleus; SNr: Substantia nigra pars reticulata; SNc: Substantia nigra pars compacta. 
 
These nuclei project inhibitory axons to the thalamus, a brain region of the diencephalon 
which in turn projects to higher cortical regions and is thought to have a “selective mediator” 
role for prethalamic signals to be interpreted by the cortex (Alexander et al., 2006; Jones, 
2002; Percheron et al., 1996). In patients affected by Huntington’s Disease, this circuitry 
appears to be severely disturbed due to the almost complete loss of medium-sized spiny 
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neurons in the striatum (Figure 3, right side). The decreased inhibitory signaling from the 
striatum to other subcortical nuclei of the basal ganglia leads to overexcitation of the thalamus 
and is thought to be responsible for the various psychiatric and motor symptoms seen in 
Huntington’s Disease. 
 
2.1.4 Metabolic defects in Huntington’s Disease 
Because of the severe brain atrophy and the resulting clinical symptoms, Huntington’s 
Disease is primarily considered to be a neurodegenerative disorder. However, over the past 
four decades it has become more and more apparent that this is a too restrictive disease 
definition and that patients display various symptoms which are most likely connected to 
widespread, systemic metabolic defects. Early studies in the 1960s and 70s reported a 
dysfunction in amino acid, glucose and fatty acid metabolism (Perry et al., 1969; Phillipson 
and Bird, 1977; Podolsky and Leopold, 1977) as well as weight loss in Huntington’s Disease 
patients (Bruyn and von Wolferen, 1973). Further studies found that this massive weight loss 
occurs despite sufficient calorie intake and that weight loss cannot be simply explained by the 
increased and uncontrollable muscle movements associated with Huntington’s Disease (Farrer 
and Meaney, 1985; Kremer and Roos, 1992; Morales et al., 1989; Sanberg et al., 1981). These 
findings as well as reports of increased prevalence of diabetes mellitus in Huntingon's Disease 
patients (Farrer, 1985), support the hypothesis of a general, systemic metabolic defect caused 
by Huntington’s Disease. 
Over the last decade, detailed metabolomic studies became feasible due to the emergence and 
improvement of sensitive detection methods like nuclear magnetic resonance (NMR) or gas 
chromatography-time-of-flight-mass spectrometry (GC-TOF-MS). Metabolic profiling of 30 
Huntington’s Disease and 20 healthy patients reported dysregulation of amino acid 
metabolism in Huntington’s Disease, verifying the earlier studies (Underwood et al., 2006). 
The study identified several metabolites such as leucine, ethylene glycol and hydroxybutyric 
acid with serum levels differing significantly between asymptomatic gene carriers and patients 
with first disease symptoms, thus providing a possible biomarker profile for disease onset and 
early disease progression. However, additional, larger scaled metabolomic studies are needed 
to verify these results. 
 
2.1.5 Current treatment possibilities of Huntington’s Disease 
Even though over 110 clinical phase I to III trials for Huntington’s Disease have been reported 
(Bonelli et al., 2004), no treatment recommendation of clinical relevance has emerged. In fact, 
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only very limited symptomatic treatment possibilities for Huntington’s Disease exist which 
can be subdivided into three classes: treatment of motor disturbances, treatment of psychiatric 
alterations and neuroprotective treatments (Bonelli and Hofmann, 2007; Bonelli et al., 2004; 
Walker, 2007).  
Treatment of motor impairments mostly focus on using antipsychotic drugs to decrease chorea 
such as haloperidol (Barr et al., 1988; Girotti et al., 1984; Leonard et al., 1975) or 
tetrabenazine (Jankovic and Beach, 1997; Ondo et al., 2002). While showing significant 
improvements on the Unified Huntington’s Disease Rating Scale in some of the studies, 
regular side-effects limit their use for clinical treatment. An alternative treatment strategy is 
based on the “excitotoxin theory” which proposes an excess of excitatory neurotransmitters 
such as glutamate as reason for the motor impairments and neurodegeneration (DiFiglia, 
1990). In an attempt to counter this overexcitatory stimuli, NMDA-receptor antagonists such 
as ketamine or riluzole have been tested in clinical trials. While ketamine failed to show any 
beneficial effects and to the contrary caused a decline in memory performance (Murman et al., 
1997), riluzole improved chorea symptoms in a number of earlier studies (Group, 2003; 
Bodner et al., 2001; Rosas et al., 1999; Seppi et al., 2001). However, a recent larger European 
level I trial with 537 patients did not report any neuroprotective or beneficial symptomatic 
effects (Landwehrmeyer et al., 2007). 
Attempts to ameliorate the psychiatric symptoms associated with Huntington’s Disease are 
mostly aimed at treating the frequent cases of depression and dementia. Common 
antidepressants like fluoxetine (Como et al., 1997; De Marchi et al., 2001) or clozapine 
(Bonuccelli et al., 1994; Colosimo et al., 1995; Sajatovic et al., 1991) showed positive results 
in case studies but larger controlled trials against depression in Huntington’s Disease are 
necessary for verification. Mild beneficial effects against dementia have been reported for 
riluzole (Seppi et al., 2001) and minocycline (Bonelli et al., 2003) in open-label trials, but 
generally no approved dementia treatment exists for Huntington’s Disease patients. 
The efficacy of neuroprotective treatments is more difficult to access because of the lack of 
reliable markers. Nevertheless, several clinical trials with potentially neuroprotective 
compounds have been reported for Huntington’s Disease. Treatment with unsaturated fatty 
acids as plasma membrane components which can alter the probability of a cell to undergo 
apoptosis showed beneficial effects in smaller studies (Puri et al., 2002; Vaddadi et al., 2002) 
but positive results could not be reproduced in a more recent and larger scaled level I trial 
(Puri et al., 2005). Similarly, treatment with the caspase inhibitor minocycline (Chen et al., 
2000; Scarabelli et al., 2004) was found to be safe, free of adverse effects at lower doses 
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(HuntingtonStudyGroup, 2004) and significantly improved motor and neuropsychological 
functions after 6 and 24 months of treatment in an open-label pilot study (Bonelli, 2004). 
However, another level III study with minocycline did not report any beneficial effects 
(Thomas et al., 2004). Critically, a recent minocycline trial with 412 ALS patients showed 
that minocycline treated patients performed significantly worse in functional capacity than 
placebo treated patients, prompting the authors of the ALS study to raise serious concerns 
about minocycline treatment in other neurodegenerative diseases, including Huntington’s 
Disease (Reynolds, 2007). Another treatment strategy has been aimed at enhancing 
mitochondrial oxidative functions known to be affected in Huntington’s Disease. Use of 
coenzyme Q10, an essential component of the mitochondrial electron transport chain (Crane 
et al., 1957), showed no beneficial effects (HuntingtonStudyGroup, 2001), whereas treatment 
with creatine resulted in an improvement of brain metabolites (Tabrizi et al., 2003; Tabrizi et 
al., 2005) as well as a decrease of serum 8-hydroxy-2'-deoxyguanosine, a marker for oxidative 
DNA injury, in Huntington’s Disease patients (Hersch et al., 2006). However, a double-blind 
placebo-controlled study showed no beneficial effect on motor symptoms or cognitive 
performance after creatine treatment for 1 year (Verbessem et al., 2003). 
Taken together, the efficacy of various potentially therapeutic compounds for Huntington’s 
Disease remains to be proven. Importantly, all clinical studies so far have been symptomatic 
treatment attempts and no potential treatment aimed at curing Huntington’s Disease or 
prolonging the life expectancy of patients exists, resulting in a very high unmet medical need 
for this disease. 
 
2.1.6 The genetics of Huntington’s Disease 
The huntingtin gene, localized on chromosome 4p16.3 (Gusella et al., 1983), was identified in 
1993 through a joint effort of six international research groups (Group, 1993a). It comprises 
67 exons and encodes for a large protein of 348 kDa whose exact function(s) remain to be 
elucidated. The mutation underlying Huntington’s Disease is an expansion of a CAG repeat 
above a pathogenic length in the coding region of exon 1 of the huntingtin gene. In healthy 
individuals, CAG length normally varies between 10 to 35 repeats while patients carrying one 
allele with 40 or more CAG repeats will develop Huntington’s Disease with 100% certainty. 
Repeat sizes of 36 to 39 are associated with a reduced disease penetrance (Andrew et al., 
1993; Brinkman et al., 1997; Duyao et al., 1993) (Figure 4). 
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Figure 4: Distribution of CAG repeat sizes in healthy and Huntington’s Disease patients, taken and 
modified from Myers, 2004. Healthy patients (green area) carry repeats between 10 and 35 with the most 
common repeat lengths being 17 to 20 CAG triplets. Individuals with a CAG repeat size of 40 or more will 
develop Huntington’s Disease. Repeat sizes from 36 to 39 can result in development of Huntington’s Disease but 
penetrance is reduced and so far unknown factors seem contribute to the development of disease symptoms. 
 
It should be noted that even though the length of the CAG repeat generally correlates 
statistically well with the age of onset, the strength of this correlation is mostly due to a small 
number of early-onset Huntington’s Disease cases with a CAG repeat length of 60 or more. 
However, the vast majority of Huntington’s Disease patients (~95%, (Myers, 2004)) carry a 
repeat length between 40 to 55 CAGs. When plotting the CAG repeat size against the age of 
onset it becomes apparent that for the majority of Huntington’s Disease patients, CAG repeat 
length is an insufficient predictor for age of onset as e.g. patients with a CAG repeat length 
between 40 and 44 can display first Huntington’s Disease symptoms as early as ~30 years of 
age and as late as ~70 years of age (Figure 5).  
 
 
 
 
 
 
 
 
 
Healthy Development of HD 
HD development dependent on 
so far unknown factors
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Figure 5: CAG repeat length and age of onset in Huntington’s Disease, taken and modified from Wexler et 
al., 2004. For CAG repeat sizes between 40 and 58, repeat size accounts for 44% of the variance in age of onset 
with a correlation coefficient of r = -0.66 (light red area). Longer repeat sizes result in early onset forms of 
Huntington’s Disease (dark red area). In these juvenile forms of Huntington’s Disease, age of onset correlates 
stronger with repeat length (r = -0.81) and CAG repeat length accounts for 72% of variance in age of onset. 
 
The search for genetic modifiers for age of onset besides the CAG repeat length in the 
huntingtin gene yielded several candidates which seem to modulate age of onset independent 
of CAG repeat length such as glutamate receptor GRIK2 (GluR6) (Chattopadhyay et al., 
2003), human caspase activated DNase (hCAD) (Chattopadhyay et al., 2005), ubiquitin 
carboxy-terminal hydrolase L1 (UCHL1) (Metzger et al., 2006b), drosophila homeobox 
homologue 1 (MSX1) (Djousse et al., 2004), NMDA receptor subunits (Arning et al., 2005), 
apolipoprotein E ε2ε3 (Kehoe et al., 1999), huntingtin interacting proteins HIP1 and HIP14 
(Metzger et al., 2006a). While these multiple genetic findings are encouraging, verified 
functional connections in terms of disease modifying mechanisms of action for these 
candidate genes are still lacking. 
 
2.1.6.1 Genetic anticipation in Huntington’s Disease 
A striking feature of Huntington’s Disease genetics is the unstability of the CAG repeat length 
from one generation to the next. In approximately 75% of all Huntington’s Disease cases, the 
CAG length changes, with expansion of the repeat length being more common than repeat 
contraction (Wheeler et al., 2007). Since repeat length correlates with age of onset, an earlier 
Strong correlation between age of 
onset and CAG repeat size
Poor correlation between age of 
onset and CAG repeat size
CAG repeat size
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disease phenotype is often observed in successive generations (Ridley et al., 1988; Ridley et 
al., 1991). This phenomenon termed “genetic anticipation” was first reported for myotonic 
dystrophy, another trinucleotide repeat disorder (Fleischer, 1918; Fu et al., 1992; Howeler et 
al., 1989; Penrose, 1948) and has since been observed in several trinucleotide repeat disorders 
(Gouw et al., 1994; Ikeuchi et al., 1995; Koide et al., 1994; Ranum et al., 1994; Takiyama et 
al., 1999; Vaisanen et al., 1996). 
The molecular mechanisms responsible for the trinucleotide instabilities are not yet fully 
understood. In Huntington’s Disease, epidemiologic reports showed that decreased age of 
onset is often associated with paternal inheritance (Barbeau, 1970; Bird et al., 1974; 
Conneally, 1984; Ridley et al., 1991; Wheeler et al., 2007), indicating a possibly increased 
gametic CAG repeat instability in sperm cells, a finding that was later confirmed in molecular 
studies (Leeflang et al., 1995; MacDonald et al., 1993). Because of these reports, erroneous 
DNA replication was long speculated to be solely responsible for the repeat length instability. 
However, more recent studies showed increased CAG repeat length mosaicism not only in 
gametic cells but also in somatic brain tissue where the CAG repeat length elongations in 
different brain regions correlated well with Huntington’s Disease neuropathology, with the 
striatum and the cerebral cortex displaying the largest repeat elongations (Kennedy et al., 
2003; Shelbourne et al., 2007; Telenius et al., 1994). While the observed somatic instability in 
different brain regions in human tissue might still be due to instability in replicating non-
neuronal cells rather than postmitotic neurons, a recent publication proved specific CAG 
instability even in non-replicating, terminally differentiated neurons in mouse models of 
Huntington’s Disease. Furthermore, this study showed an increased CAG repeat instability in 
neuronal cells dissected from human striata when compared to non-neuronal cell types 
(Gonitel et al., 2008).  
 
2.1.7 Huntingtin Protein 
2.1.7.1 Wild-type huntingtin 
Wild-type huntingtin is a 3144 amino acids large, soluble protein which is ubiquitously 
expressed, with highest expression levels in testes and the central nervous system (Figure 6). 
It has no relevant sequence homology with other proteins and its potentially complex cellular 
functions are poorly understood. Subcellular localization showed huntingtin association with 
the nucleus (Kegel et al., 2002), the Golgi complex, the endoplasmatic reticulum (Hilditch-
Maguire et al., 2000), synaptic vesicles (DiFiglia et al., 1995; Velier et al., 1998), the 
microtubule network (Hoffner et al., 2002) as well as mitochondria (Orr et al., 2008; Petrasch-
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Parwez et al., 2007; Rockabrand et al., 2007). Huntingtin contains 36 HEAT domains which 
are supposed to be involved in protein-protein-interactions (Andrade and Bork, 1995) and 
consist of a series of three amino acids which are repeated ~10 times along a 37-47 amino 
acid stretch. Huntingtin also contains a carboxyterminal nuclear export signal (Xia et al., 
2003), indicating a possible role as a cytosol-nucleus transporter protein or as a transcription 
modulating protein. The aminoterminal part of huntingtin contains various protease cleavage 
sites (Gafni and Ellerby, 2002; Gafni et al., 2004; Goldberg et al., 1996; Wellington et al., 
2002; Wellington et al., 1998; Wellington et al., 2000b) and the polyglutamine repeat which is 
expanded in Huntington’s Disease (Group, 1993a). Importantly, polyglutamine rich regions 
are also found in transcription factors like TBP or CREB (Everett and Wood, 2004; Friedman 
et al., 2008; Kim et al., 2002; McCampbell et al., 2000; Perez et al., 1998; van Roon-Mom et 
al., 2005). The cleavage and subsequent release of the aminoterminal segment containing the 
polyglutamine sequence facilitates fragment localization to the nucleus (Davies et al., 1997; 
DiFiglia et al., 1997; Kim et al., 2001; Lunkes et al., 2002).  
 
H2N COOH
1    250       500       750       1000                      1500                        2000                     2500          3144
: Polyglutamine tract : Region with several cleavage sites
: Polyproline sequence : Nuclear export signal
: HEAT repeat clusters : Serine phosphorylation sites
: Ubiquitination/Sumoylation site  
Figure 6: The huntingtin protein. Huntingtin is a 348 kDa large protein whose wild-type functions are still to 
be elucidated. The protein consists of numerous HEAT repeats which are hypothesized to be involved in protein-
protein interactions, a polyglutamine region mutated at the aminoterminal part in Huntington’s Disease, a 
polyproline region supposed to enhance protein solubility and a region containing several caspase and calpain 
cleavage sites. Several posttranslational modifications such as aminoterminal SUMOylation/ubiquitination or 
serine phosphorylations have been reported which are hypothesized to influence mutant huntingtin toxicitiy. 
 
Wild-type huntingtin is reported to have numerous cellular functions. Studies showed that it is 
anti-apoptotic through inhibition of pro-caspase9 cleavage and caspase 3 activation (Leavitt et 
al., 2006; Rigamonti et al., 2000; Rigamonti et al., 2001), it controls the cortical production of 
BDNF, a neurotrophin known to regulate striatal survival (Alcantara et al., 1997; Fusco et al., 
2003; Nakao et al., 1995; Zuccato et al., 2001; Zuccato et al., 2005; Zuccato et al., 2003), it is 
involved in vesicular transport (Gauthier et al., 2004; Gunawardena et al., 2003; Trushina et 
al., 2004) and it is reported to be involved in regulating gene transcription (Dunah et al., 2002; 
Holbert et al., 2001; Zuccato et al., 2001). 
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2.1.7.2 Gain-of-function or loss-of-function? 
Despite these numerous reported functions of wild-type huntingtin for normal cellular 
mechanisms and survival, Huntington’s Disease is widely considered a gain-of-function 
disease which is caused by newly adopted toxic properties of the mutated protein rather than a 
loss-of-function disease. This is supported by several observations. First, heterozygote knock 
out mouse models with loss of one wild-type huntingtin allele do not show any disease 
phenotype (Duyao et al., 1995; Zeitlin et al., 1995) while heterozygote mutant huntingtin 
knock-in mouse models display Huntington’s Disease like symptoms (Lin et al., 2001; 
Shelbourne et al., 1999). Second, transgenic mouse models which express mutant huntingtin 
or mutant huntingtin fragments in addition to the normal levels of endogenous wild-type 
huntingtin, suffer from strikingly severe neurodegeneration and Huntington’s Disease 
symptoms (Hodgson et al., 1999; Hurlbert et al., 1999; Mangiarini et al., 1996; Reddy et al., 
1998; Schilling et al., 1999; Shehadeh et al., 2006). Similarly, rat models with artificial 
expression of mutant huntingtin through lentiviral delivery exhibit Huntington’s Disease 
symptoms despite the presence of two endogenous wild-type huntingtin alleles (de Almeida et 
al., 2002; Regulier et al., 2004). Finally, unspecific knockdown of both wild-type and mutant 
huntingtin mRNA through RNA interference in mouse models improves disease symptoms 
(DiFiglia et al., 2007; Harper et al., 2005; Machida et al., 2006; Rodriguez-Lebron et al., 
2005; Wang et al., 2005), supporting the theory that it is not the decrease of wild-type but the 
gain of mutant huntingtin expression which causes Huntington’s Disease. However, it cannot 
be excluded that loss of wild-type function contributes to a smaller extend to disease 
development and progression. 
 
2.1.7.3 Structural changes of the mutated huntingtin protein 
As mentioned above, 100% penetrance in Huntington’s Disease is associated with a mutated 
huntingtin protein in which the aminoterminal polyglutamine sequence is expanded over a 
critical threshold of 39 glutamines. Long polyglutamine repeats can undergo a transient 
conformational change in which the random-coil adopts a polar zipper conformation that is 
stabilized by hydrogen bonds between the amides (Figure 7) (Perutz et al., 1994). The newly 
formed polar zipper conformation results in a cylindrical, parallel ß-sheet structure with one 
helical turn requiring 20 glutamines (Perutz et al., 2002a). However, this singular helical turn 
itself is unstable as the ends of the helix cannot form hydrogen bonds needed for helix 
stability. Importantly, a helix containing 40 or more glutamines displays two successive turns, 
enabling hydrogen bond formation between the two turns, thereby greatly enhancing overall 
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stability. A similar ß-sheet formation has been observed in amyloid fibrils formed by yeast 
prion protein Sup35 as well as amyloid ß peptide found in Alzheimer’s Disease (Balbirnie et 
al., 2001; Benzinger et al., 2000; Perutz et al., 2002b). In all these disorders the ß-sheet 
helices are proposed to act as a nuclearization seed for other monomers leading to fibril- and 
ultimately aggregate formation. 
Figure 7: Polymerisation events leading to aggregation of mutant huntingtin fragments, modified 
composite picture: Polar Zipper and ß-sheet helices pictures taken from Perutz et al., 2002a and Perutz et 
al., 1994, fibrils and aggregates pictures taken from Diaz-Hernandez et al., 2004. Hydrogen bonds between 
polyglutamines result in a polar zipper conformational arrangement between polyglutamine repeat stretches. 
These polar zipper strands in turn form water-filled helical ß-sheet structures whose stability increases with 
increasing polyglutamine repeat length. Assembly of several of these ß-sheet helices into fibrils leads in the end 
to the formation of large intracellular aggregates. 
 
Studies in in vitro and in vivo Huntington’s Disease models showed that full length mutant 
huntingtin has to be cleaved in order to undergo the described sequential aggregation steps 
(Cooper et al., 1998; Graham et al., 2006; Lunkes et al., 2002; Scherzinger et al., 1997; 
Scherzinger et al., 1999). It is hypothesized that uncleaved mutant huntingtin is prevented 
from fibrillar polymerization because of steric hindrance resulting from the size of the full 
length protein. The small, soluble aminoterminal mutated huntingtin fragments are then prone 
for stable conformational changes and thus have the ability to form fibrils and aggregates. 
Therefore, cleavage of mutant huntingtin and release of critical intracellular levels of mutant 
huntingtin fragments appears to be the rate limiting step in aggregate formation. 
While the conformational changes of mutant huntingtin and the subsequent formation of large 
aggregates are its most striking characteristics, the role of these mutant huntingtin aggregates 
for Huntington’s Disease are under debate and contradicting reports about aggregate toxicity 
have been published. Studies supporting a toxic role of huntingtin aggregates demonstrated 
that formation of nuclear but not cytosolic aggregates result in cell death (Bates, 2003; Chen 
et al., 2001; Chen et al., 2002; Saudou et al., 1998; Yang et al., 2002). In vivo experiments 
Polar Zipper Fibrils Aggregates
20 µm500 nm
4.8Å
Increasing scale
ß-sheet helix
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using a mouse model conditionally expressing mutant huntingtin showed that development of 
symptoms depended on the continuous expression of the transgene. Interestingly, switching 
off mutant huntingtin production not only stopped disease progression but also reversed the 
aggregate load in the mouse brain (Martin-Aparicio et al., 2001; Yamamoto et al., 2000). 
However, these findings have to be interpreted with care as they merely show correlation 
between aggregate formation and Huntington’s Disease progression and not necessarily 
causation. Reports using time-lapse single cell microscopy question the toxic role of 
huntingtin aggregates by showing that neuronal death is dependent on the amount of diffuse 
mutant huntingtin inside the cell and not the number of aggregates. Interestingly, neurons 
displaying aggregate formation seem to survive even longer than those without visible 
aggregates suggesting a neuroprotective role for aggregates as a molecular sink for soluble 
pathogenic mutant huntingtin forms (Arrasate et al., 2004; Saudou et al., 1998).  
 
2.1.8 Potential pathogenic molecular mechanisms Huntington’s Disease 
The exact cause for cell death resulting from expression of either soluble mutant huntingtin 
species or formation of insoluble huntingtin aggregates remains unclear and various toxic 
mechanisms have been suggested including impairment of vesicle transport, transcriptional 
dysregulation, mitochondrial dysfunction and proteasome blockage (Figure 8). 
 
Figure 8: Possible pathogenic mechanisms of mutated huntingtin protein, taken from Landles and Bates, 
2004.  
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Numerous groups have reported transcriptional dysregulation in Huntington’s Disease caused 
by association of different transcription factors like specificity protein 1 (SP1) (Dunah et al., 
2002; Hodges et al., 2006; Luthi-Carter et al., 2002a; Luthi-Carter et al., 2002b), cyclic AMP 
(cAMP) response element binding (CREB) protein (Glass et al., 2000; Jiang et al., 2006; 
Nucifora et al., 2001; Wyttenbach et al., 2001) or TATA-box binding protein (TBP) (Schaffar 
et al., 2004) with mutant huntingtin. As a result, these transcription factors are sequestered 
into intranuclear aggregates thereby leading to a general decrease in expression levels of their 
target genes (Figure 8, #7). 
Possibly related to the reported transcriptional dysregulations is the finding of mitochondrial 
impairment in Huntington’s Disease. Expression of the transcriptional coactivator peroxisome 
proliferator-activated receptor-gamma coactivator 1 (PGC-1alpha) is regulated by CREB 
(Herzig et al., 2001). PGC-1-alpha is a key regulator of cellular metabolism and 
mitochondriogenesis (Puigserver and Spiegelman, 2003). Interestingly, PGC-1alpha is 
consistently downregulated in Huntington’s Disease animal models as well as in patients 
resulting in mitochondrial dysfunctions (Cui et al., 2006; Weydt et al., 2006). In addition, 
PGC1-alpha knock-out mice display a specific striatal degeneration phenotype similar to the 
one observed in Huntington’s Disease (Leone et al., 2005; Lin et al., 2004). Besides these 
indirect links between mitochondrial impairment in Huntington’s Disease through 
transcriptional dysregulation, direct association of mutant huntingtin with mitochondria has 
been reported which results in specific dysfunctions of complexes II and III of the 
mitochondrial respiratory chain and oxidative damage (Orr et al., 2008; Solans et al., 2006) 
(Figure 8, #5). 
Another possible reason for mutant huntingtin toxicity could be the direct impairment of the 
ubiquitin-proteasome system. Various studies reported an inability of the proteasome 
machinery to degrade peptides containing long polyQ-repeats, resulting in a blockage of the 
proteasome degradation pathway and subsequent cellular changes of the ubiquitin system in 
Huntington’s Disease patients (Bence et al., 2001; Bennett et al., 2007; Jana et al., 2001) 
(Figure 8, #4). 
Because of the great variety of the affected cellular mechanisms in Huntington’s Disease, the 
exact reasons for mutant huntingtin toxicity are still not fully understood. Interestingly, recent 
findings suggest that efforts to pinpoint a specific pathogenic mechanism of action in 
Huntington’s Disease might be impossible as the numerous reported dysfunctions might be 
secondary due to a general, unspecific impairment in cellular protein homeostasis. This could 
be caused by the flux of misfolded proteins acting as additional stressors to the chaperone 
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system, which is responsible to keep the balance between folding, translocation and protein 
clearance (Morimoto, 2008; Prahlad et al., 2008). 
Therefore, treatments aiming to restore specifically only one impaired cellular mechanism in 
Huntington’s Disease might be condemned to fail. Thus, recent discovery work for 
therapeutics have been expanded to include potential therapies which influence the misfolding 
or the clearance of mutant huntingtin thereby tackling the most upstream event leading to 
Huntington’s Disease. This includes e.g. the upregulation of the chaperone system (Perrin et 
al., 2007; Zourlidou et al., 2007), inhibition of mutant huntingtin cleavage (Kim et al., 2006) 
or induction of the autophagy degradation pathway (King et al., 2008; Yamamoto et al., 2006).  
 
2.2 Time resolved fluorescence resonance energy transfer  
2.2.1 Fluorescence resonance energy transfer (FRET)  
The eponymous report with the first description of resonance energy transfer was published 
six decades ago by Förster (Förster, 1948). Fluorescence resonance energy transfer (FRET) is 
a quantum-mechanical phenomena based on energy coupling through the dipoles of two 
fluorescent molecules which occurs when two fluorophores are in close proximity to each 
other. Under such conditions, excitation of the donor fluorophore results in emission from the 
acceptor fluorophore at expense of donor-emission, presumed that the emission spectrum of 
the donor overlaps with the excitation spectrum of the acceptor (Stryer, 1978). Förster showed 
that efficiency of FRET (EFRET) is largely dependent on the distance “r” between the two 
fluorophores (Figure 9): 
EFRET = 1 / [1 + (r / R0)6] 
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Figure 9: FRET efficiency in dependence to the distance of the two fluorophores. 
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The Förster radius R0 is the distance for a defined fluorophore pair where EFRET equals 50%. It 
is a non-empirical value and can be calculated through: 
 
R0 = [2.8 * 1017 * κ2 * QD * εA * J(λ)]1/6 nm 
 
with κ2 being the dipole orientation factor, QD the fluorescence quantum yield of the donor 
when acceptor is absent, εA the maximum acceptor extinction coefficient and J(λ) being the 
overlap integral between donor and acceptor spectra. Since all the variables determining R0 
only influence its value by the sixth power, the normal R0 limit for FRET pairs using 
fluorophores with a strong maximum acceptor extinction coefficient as well as a high 
quantum yield of the donor is around 4 to 6 nm (Patterson et al., 2000; Wu and Brand, 1994).  
While FRET is routinely used for imaging experiments investigating e.g. protein-protein-
interactions it has some technological limitations like photobleaching or bleed-through 
between the two fluorophores (light which is supposed to excite only the donor also excites 
directly the acceptor fluorophore because of overlap in the excitation spectra). More 
importantly for drug discovery purposes, a further limitation inherent to the nature of FRET 
exists which complicates its application in high-throughput compound screens. In large 
automated primary screens designed to test 100’000 to over 1 millions compounds with a 
sample size of n=1, readout reliability and assay robustness is a prerequisite for any successful 
screen. Since FRET is severely affected by numerous possible screening artifacts such as 
autofluorescence of compounds or cellular components as well as light scattering resulting 
from precipitating compounds, FRET based readouts become highly unreliable under most 
high-throughput screening conditions. However, a related technology termed time resolved 
FRET can overcome most of these limitations. 
 
2.2.2 Time resolved FRET 
The disadvantages of normal FRET for high-throughput screening can be overcome by the 
use of rare earth complexes. These complexes are characterized by an organic trisbypyridine 
cryptate which engulfs a lanthanide ion such as europium3+ (Alpha et al., 1987). Light 
excitation of the complex results in a controlled energy transfer from the organic cage to the 
europium3+ ion. The lanthanide ion subsequently emits a very long-lived fluorescence which 
is not affected by photobleaching.  
For several reasons, these properties make the europium cryptate an excellent donor 
fluorophore for a time resolved FRET when used in combination with an acceptor fluorophore 
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(Mathis, 1993). First, rare earth ion cryptates display very large Förster radii of up to 9 nm as 
opposed to the 4 to 6 nm found in common fluorophores, enabling acceptor-donor interactions 
over much larger distances, thus simplifying their use for immunodetection methods (Bazin et 
al., 2001). Second, the unique long-lived emission from the cryptate-ion complex allows for 
time-dependent separation of the fluorescence artifacts which limit normal FRET assays from 
the specific time delayed excitation of the FRET acceptor fluorophore (Figure 10). Third, the 
possibility of time resolved measurements for wavelengths specific for the donor as well as 
the acceptor fluorophore results in a ratiometric readout which automatically corrects for 
assay volume errors as well as signal quenching or scattering, thereby increasing assay 
robustness and reliability (Imbert et al., 2007). 
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Figure 10: Schematic presentation of time resolved FRET. The time dependent intensity decay for four 
different fluorescence signals in a homogenous sample system where fluorophore-labeled antibodies are present 
in excess over their antigen is shown. After excitation of the sample, the matrix background fluorescence  (grey) 
of the sample and the fluorescence resulting from the direct flash excitation of the acceptor fluorophore-labeled 
antibody (dark blue) decrease rapidly. Introducing a time delay of ~100 µs between sample excitation and 
fluorescence measurement therefore allows for separation of this nonspecific fluorescence from the specific time 
resolved FRET signal. In contrast to this short lived matrix fluorescence, the europium cryptate donor 
fluorophore-labeled antibody displays a very long lived (up to 1 ms) emission after flash excitation (red). When 
the donor fluorophore-labeled antibody and the acceptor fluorophore-labeled are in close proximity to each other 
as a result of binding to the same antigen, a fluorescence resonance energy transfer occurs between the two 
fluorophores thus resulting in a time resolved FRET signal (light blue) whose intensity is directly proportional to 
the amount of antigen present in the sample. 
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3 AIMS OF THE THESIS 
At present, the pathogenesis of mutant huntingtin remains enigmatic, also due to insufficient 
characterization and quantification of the interplay between soluble and aggregated mutant 
huntingtin species. Therefore, my goal was to monitor huntingtin protein levels in its soluble 
and aggregated form and to find new methods and treatments to characterize or influence the 
balance between these conformational species.  
In order to study mutant huntingtin levels under controlled conditions, my first goal was to 
establish a cellular model system recapitulating major aspects found in Huntington’s Disease 
patients such as aggregation of mutant huntingtin and transcriptional dysregulation. As the 
precise pathogenic mechanisms of mutant huntingtin protein in neurons are yet not fully 
understood, the cellular model should display greatest possible flexibility to study the effect of 
wild-type and mutant huntingtin expression under a variety of cellular conditions. Using my 
cellular model, I aimed to establish a biochemical method for the precise and sensitive 
quantification and characterization of huntingtin aggregates. 
In parallel, since only symptomatic treatments for Huntington’s Disease exist, another goal of 
this thesis was to develop a highly sensitive, rapid, automated and robust quantification assay 
based on time resolved fluorescence resonance energy transfer. This assay enabled me to 
examine new therapeutic approaches by identifying compounds which directly modify the 
level of mutated huntingtin protein. In addition, if the search for compounds lowering mutant 
huntingtin in the cellular model is successful, I needed to establish a method enabling me to 
monitor the amount of mutant huntingtin during disease progression also in living human 
patients. I therefore aimed at creating a novel bioassay with reliable and easy quantification of 
human mutant huntingtin in readily accessible tissue samples.  
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4 RESULTS 
4.1 Inducible mutant huntingtin expression in a neuronal cell model leads to 
transcriptional dysregulation and cell death 
 
Andreas Weiss, Dorothee Bleckmann, Stephan Grueninger, Muriel Stefani, Natacha 
Stoehr, Emmanuel Lacroix, Miriam Bibel, Etienne Régulier and Paolo Paganetti  
 
Neuroscience Discovery, Novartis Institutes for BioMedical Research, Basel, Switzerland  
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4.1.1 SUMMARY 
Expansion of a polyglutamine repeat at the aminoterminal part of huntingtin protein leads to 
Huntington’s Disease, an autosomal-dominant neurodegenerative disorder characterized by 
impaired motor performance and severe brain atrophy. The proposed pathogenic cellular 
mechanisms of mutant huntingtin protein are numerous and include formation of intracellular 
huntingtin protein aggregates, transcriptional dysregulation, neurite dystrophy and 
mitochondrial dysfunction. Here, we describe a novel neuronal model with inducible 
expression of wild-type and mutant huntingtin fragments under proliferating and 
differentiating conditions. We further demonstrate that the induced expression of 
aminoterminal fragments of mutant huntingtin causes transcriptional dysregulation and 
cellular dysfunction. Recapitulation of the pathogenic findings from human patients in these 
cells recommends this neuronal model for further investigations of the biological mechanism 
of mutant huntingtin, allowing us to characterize the development and the pathology of 
Huntington’s Disease on a cellular level. 
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4.1.2 INTRODUCTION 
Huntington’s Disease (HD) is an inherited, autosomal-dominant neurodegenerative disorder 
whose main clinical symptoms include chorea, cognitive decline and weight loss (Nance and 
Sanders, 1996; Young et al., 1986). Patients normally display first disease symptoms in mid-
age with a relentless disease progression and premature death 15 to 20 years after appearance 
of clinical symptoms (Foroud et al., 1999). The disorder is caused by a mutated and expanded 
polyglutamine (polyQ) stretch in the huntingtin protein (Htt), a 348 kDa large, ubiquitously 
expressed protein with yet unclear cellular function (Group, 1993a; Gusella et al., 1983). 
Cleavage of full-length mutated Htt leads to the release of aggregation prone aminoterminal 
Htt fragments carrying the expanded polyQ repeat (Cooper et al., 1998; Lunkes et al., 2002; 
Scherzinger et al., 1999). The cause for cell death as a result of mutant Htt expression is yet 
not fully understood and different pathogenic mechanisms have been proposed, including 
impaired axonal trafficking and microtubule destabilization (Gunawardena et al., 2003; 
Trushina et al., 2003), transcriptional dysregulation (Hodges et al., 2006; Jiang et al., 2006; 
Schaffar et al., 2004; Wyttenbach et al., 2001) and mitochondrial dysfunction (Solans et al., 
2006). 
Various cellular models for HD have been developed to study the effect of mutant huntingtin 
expression on cellular mechanisms. Non-neuronal primary cells from HD patients have been 
used to study CAG repeat variability (Manley et al., 1999a) or calcium homeostasis (Sawa et 
al., 1999). Expression of mutant Htt in murine primary neuronal cultures results in neuritic 
degeneration and induction of apoptotic pathways (Li et al., 2000; Saudou et al., 1998). 
Immortalized striatal neurons showed increased vulnerability to mitochondrial toxins and 
impaired mitochondrial complex II function in presence of stable mutant Htt expression (Ruan 
et al., 2004; Trettel et al., 2000). 
While the use of primary neuronal cultures or stable expressing cell lines vastly increased the 
understanding of HD pathology, such cellular models display several drawbacks for their use 
in drug discovery purposes such as the limited availability of primary cultures and the 
possible adaptation to the toxic insult in cell lines stably expressing mutant Htt. To overcome 
these disadvantages, we developed a neuronal model which recapitulates cellular dysfunctions 
seen in HD patients but is available in unlimited cell numbers and provides flexibility for 
future experiments. We chose the neuroblastoma line HN10, a readily transfectable neuronal 
line which can be cultured under mitotic and post-mitotic conditions (Lee et al., 1990; 
Sommerfeld et al., 2000). To eliminate adaptational clonal effects, we created HN10 cell lines 
with inducible expression of different wild-type and mutant Htt constructs. In this study, we 
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show that this inducible neuronal model reproduces key pathogenic mechanisms found in HD 
patients and provides a valuable in vitro system for drug discovery research in HD. 
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4.1.3 MATERIAL AND METHODS 
Cell culture 
For keeping the HN10 cells in a mitotically active state, cultures were grown in proliferating 
media (high-glucose DMEM (Gibco), 10% FCS, penicillin + streptomycin) at 37°C and 5 % 
CO2. Exchange of the medium and splitting of the cells occured every 2-3 days. In order to 
keep the cells under differentiating, post-mitotic conditions, proliferating cells were collected 
and resuspended in proliferating media and plated in 20% confluency on dishes precoated 
with 20 µg/µl laminin (SIGMA). After 1 day, proliferating media was removed and cells were 
cultured in differentiating media (serum-free media, supplements (Brewer et al., 1993), 45 µM 
retinoic acid (SIGMA)) until time of the readout. For immunohistochemistry, cells were fixed 
with 4% paraformaldehyde and stained with the anti-huntingtin antibody 2B7 (custom 
designed by GENOVAC, Freiburg, Germany), the anti-huntingtin mEM48 antibody 
(Millipore, MAB 5374) or the anti-polyglutamine antibody m1C2 (Millipore, MAB 1574) and 
Hoechst nuclei stain (Invitrogen) according to standard immunohistochemistry protocol.  
 
Creation of stable inducible clones 
Parental HN10 cells were transfected with the receptor pNEBR-R1 plasmid part of the 
inducible rheoswitch mammalian system (New England Biolabs). Transfected cells were 
seeded in a dilution series on 96-well plates to statistically achieve singular clones in the 
higher diluted wells and cultured under selection with 1 mg/ml geneticin (Invitrogen). After 2 
weeks of selection, >30 identifiable clone colonies from the highest diluted wells were picked 
and reseeded on a 24-well plate. Selected clones were compared to the parental HN10 cell line 
in terms of morphology, speed of growth and their ability to differentiate. After this 
preselection 21 remaining clones were transiently transfected with a luciferase reporter 
plasmid and cultured for 2 days with or without inducer. Clone with best induction ratio was 
selected to develop four stable HN10 cell lines with inducible expression of the 
aminoterminal huntingtin fragments exon1-25Q, exon1-72Q, aa857-25Q and aa857-72Q.  
 
Western blot and AGERA 
Monomeric and aggregated huntingtin fragments were detected by western blot or AGERA as 
described in Weiss et al., 2008. 
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Real time PCR 
Exon1-72Q clone was cultured under proliferating or differentiating conditions with or 
without inducer. RNA was isolated with RNeasy Mini kit (Qiagen). Real time PCR was 
performed with customized TaqMan® microfluidic card arrays (Applied Biosystems) 
according to manufacturers protocol. Eight different samples were analyzed simultaneously 
for 15 probes + 18S control. 100 to 150 ng of total RNA were used in the First-Strand cDNA 
synthesis according to manufacturers protocol (Invitrogen, SuperScript III Platinum). The 
cDNA was added to the microfluidic card using 30 µl cDNA, 50 µl 2x Platinum qPCR 
SuperMix-UDG with ROX and 100 µl DEPC water. After two centrifugations at 1000 g for 1 
min, the micro fluidic card was sealed and analyzed. After an incubation at 50°C for 2 min, 
samples were denatured at 94.5°C for 2 min. The following parameters were then set for 
optimal amplification of selected probes during 45 cycles: 97°C for 30 sec and 59.7°C for 1 
min. Data were extracted and Ct values normalized by 18S calibration.  
 
Protein and aconitase measurements 
For protein and aconitase measurements, proliferating or differentiating HN10-exon1-72Q 
clone was cultured on 24-well plates under noninduced or induced conditions. After 1, 2 and 3 
days of cell culture, wells were washed 3x with PBS and protein content of each well was 
measured with BCATM Protein Assay Kit (Perbio). The aconitase activity assay was adapted 
from previously described methods (Gardner et al., 1994; Hausladen and Fridovich, 1996). 
Briefly, wells were washed with 100 µl of PBS followed by addition of 30 mM sodium citrate, 
0.5 mM MnCl2, 50 mM Tris, 0.2 mM NADP, 2 U/ml isocitrate dehydrogenase, 1 % Triton, 
pH 7.5. After mixing, kinetic measurements were done at 37°C in Fluoroskan microplate 
fluorometer with 355/460 nm over 30 min. 
 
Neurite quantification 
Analysis of neurite outgrowth was performed with LI-COR Biosciences In-Cell Western™ 
assay. Exon1-25Q and exon1-72Q clone were cultured under differentiating conditions with 
or without inducer for up to 6 days on clear 96-well plates. HN10 neurites can be visualized 
with anti-tubulin immunohistochemistry. For this, cells were fixed with 4% paraformaldehyde 
and stained with anti-tubulin (Abcam). After washing, cells were incubated with IRDye 
800CW anti-mouse secondary antibody (LI-COR Biosciences) and DRAQ5™ nuclei stain 
(Biostatus Limited). Quantification of tubulin and nuclei was performed with Odyssey® 
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imager & software (LI-COR Biosciences). The ratio of tubulin stain and cell number (nuclei 
stain) reflected the amount of neurites per cell formed under the different conditions. 
 
Caspase 3/7 activity 
Exon1-25Q and exon1-72Q clone were cultured under differentiating conditions with or 
without inducer for up to 5 days on an opaque 96-well plates. Caspase 3/7 activity was 
determined using the Caspase-Glo 3/7 Assay (Promega) as recommended by the manufacturer 
using a RUBYstar reader (BMG Labtech). 
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4.1.4 RESULTS 
Inducible expression of wild-type and mutant huntingtin fragments in a neuronal cell 
line 
Aminoterminal mutant huntingtin fragments carrying an expanded polyQ stretch are toxic in 
vitro and in vivo through a gain-of-function mechanism but the precise pathogenic cellular 
mechanism are yet not fully understood (Arrasate et al., 2004; Hurlbert et al., 1999; 
Mangiarini et al., 1996; Schilling et al., 1999; Varma et al., 2007). To examine in detail toxic 
mechanism(s) of action of mutant huntingtin fragments, in vitro models are needed which 
recapitulate the cellular defects found in patients. We thus generated four stable neuronal 
HN10 clone lines with inducible expression of short (exon1) or long (aa857) amino-terminal 
Htt fragments carrying either a wild-type (25Q) or a mutant (72Q) polyQ length (Figure 11A). 
All cell lines displayed no basal expression, whereas the expression levels of Htt fragments 
were readily detectable upon induction (Figure 11B). Expression of Htt was confirmed by 
immunohistochemistry. Notably, only the expression of the exon1-72Q fragment resulted in 
visible aggregate formation in a subset of cells (Figure 11C).  
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Figure 11: Inducible expression of wild-type and mutant huntingtin fragments in clonal HN10 cell lines. A: 
Wild-type (25Q) and mutant (72Q) huntingtin fragments used for creation of stable and inducible HN10 clones 
in comparison to the endogenous full length huntingtin. B: Western blots of huntingtin expressing HN10 clones 
cultured with or without inducer. No basal expression is detectable in absence of inducing ligand. C: 
Immunohistochemistry of huntingtin expressing HN10 clones cultured with or without inducer. After 5 days of 
induction, expression of exon1-72Q fragment leads to aggregate formation in a subset of cells (arrow) whereas 
clones expressing exon-25Q, aa857-25Q and aa857-72Q do not show any detectable aggregate formation. 
 
After the addition of inducer, an increase in Htt fragment levels was observed over 24 hours, 
whereas the subsequent removal of the inducer from the culture medium caused a time 
dependent decrease of the Htt fragments (Figure 12A and Figure 12B). Further quantification 
of fragment expression levels revealed a dose dependency correlating with the concentration 
of the inducer in the culture medium (Figure 12C). Supporting the immunohistochemical 
observation, aggregate formation after induction of exon1-Q72 expression was confirmed 
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with AGERA (Weiss et al., 2008) (Figure 12D) while expression of the two wild-type 
constructs or of the larger aa857-72Q construct did not lead to any detectable aggregate levels 
even when using this sensitive biochemical aggregate detection method (data not shown).  
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Figure 12: Time dependent induction of exon1-Q72 monomer expression and aggregation formation. A: 
Addition of inducer to the culture medium leads to a time dependent increase of exon1-72Q expression with first 
detectable protein levels after 6 h (biological triplicates). B: Removal of the inducer from the culture medium 
leads to decreasing exon1-72Q levels over time. C: Increasing inducer concentrations to the culture medium of 
exon1-25Q, exon1-72Q, aa857-25Q and aa857-72Q clones reveal dose dependent huntingtin fragment 
expression response for all 4 clones (western blot quantification). D: AGERA blot of noninduced or induced 
exon1-72Q cells reveals detectable aggregate levels after induction.  
 
A common finding in HD models is that the length of the huntingtin construct carrying the 
polyQ repeat influences aggregate formation and severity of disease symptoms. Full length 
mutant huntingtin is cleaved into smaller fragments (Lunkes et al., 2002; Ratovitski et al., 
2007; Scherzinger et al., 1999) and decreased mutant huntingtin fragment length correlates 
with increased disease progression and aggregate formation (Kim et al., 2001; Martindale et 
al., 1998; Schilling et al., 2007; Weiss et al., 2008). Further work focused on characterizing 
the HN10-exon1-Q72 cell line as it expresses the shortest aminoterminal mutant fragment 
which is most prone to aggregate. Since mutant huntingtin aggregation and impairment of cell 
viability is most pronounced in differentiated adult neuronal cells (DiFiglia et al., 1997; 
Fennema-Notestine et al., 2004; Li et al., 2000; Macdonald and Halliday, 2002; Rosas et al., 
2003), it was important that our cellular model can be cultured under mitotic and post-mitotic 
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conditions (Figure 13), therefore allowing for analysis of exon1-72Q expression effects under 
proliferating as well as differentiating conditions. 
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Figure 13: HN10 cells can be grown under proliferating and differentiated conditions. Adjusting the culture 
conditions allows for controlled differentiation of the normally proliferating HN10 cells. Staining with tubulin 
(red) and Hoechst nuclei stain (blue) reveals the dense neurite network formed after 7 days of differentiation. 
(representative pictures, all bars=100 µm). 
 
Exon1-72Q expression decreases PGC1-alpha levels and impairs cellular viability  
One of the major characteristics of HD is transcriptional dysregulation. Transcription factors 
such as specificity protein 1 (SP1) (Dunah et al., 2002; Hodges et al., 2006; Luthi-Carter et al., 
2002a) and cAMP response element binding (CREB) protein (Jiang et al., 2006; Nucifora et 
al., 2001; Wyttenbach et al., 2001) can interact with mutant huntingtin and get sequestered 
into intranuclear aggregates, resulting in a decreased transcription of their target genes. To 
examine the relevance of our model for transcriptional dysregulation as a result of mutant 
huntingtin expression, we analyzed the expression levels of several genes which are under the 
promoter control of SP1 or CREB. First, we compared gene expression in noninduced 
proliferating versus differentiating HN10-exon1-72Q cells. As expected, keeping the cells in a 
proliferative active or in differentiated state resulted in different gene expression patterns 
(Figure 14A). Expression of transcriptional coactivator peroxisome proliferator-activated 
receptor-gamma coactivator 1 (PGC-1alpha), a CREB dependent master regulator of 
mitochondriogenesis (Puigserver and Spiegelman, 2003), was found to be upregulated in 
noninduced differentiating cells, possibly reflecting the increased energetic demand of 
differentiating cells due to extensive neurite formation. Differences in basal PGC-1alpha 
expression levels were of special interest for establishing a valid cellular HD model, as human 
PGC-1alpha is one of the key genes found to be constantly downregulated in HD patients (Cui 
et al., 2006; Weydt et al., 2006). When analyzing the effect of induced exon1-72Q on gene 
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expression we detected a downregulation of PGC-1alpha in proliferating (Figure 14B) as well 
as in differentiating cells (Figure 14C). 
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Figure 14: Differences in transcriptional dysregulation in proliferating and differentiated HN10 cells with 
or without exon1-72Q induction. A: Real-time PCR for 15 genes of interest in Huntington’s Disease reveals 
influence of culture conditions on gene expression in noninduced HN10 exon1-72Q clone with pronounced 
upregulation of PGC1A expression (~6-fold) upon differentiation. B: Induced expression of exon1-72Q in 
proliferating cells results in significant downregulation of PGC1A and TFAM, genes known do be also 
decreased in Huntington’s Disease patients. C: Expression of exon1-72Q in differentiated cells reproduces the 
significant downregulation of PGC1A. (All graphs: n=3, p<0.05=*, p<0.01=**, p<0.001=***). 
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Next, we examined whether expression of mutant Htt fragment and the downregulation of 
PGC-1alpha influenced cell viability or mitochondrial function. For this, cells were cultured 
under proliferating or differentiating conditions with or without induction of exon1-72Q for 
three days and cellular protein levels were measured to determine general cell viability. 
Cellular protein amounts increased with time when culturing the cells under proliferating 
conditions, reflecting the mitotic nature of the cells (Figure 15A, upper graph). A small but 
not significant decrease in cellular protein levels was detected after 3 days in the proliferating 
clones with exon1-72Q expression compared to proliferating noninduced clones. The 
influence of exon1-72Q expression increased when keeping the clone under differentiating, 
non-dividing conditions. Significant decrease of cellular protein levels between noninduced 
and induced cells were detected already after 2 days of exon1-72Q expression and differences 
increased after 3 days of induction, indicating a general impairment of cell viability as a result 
of mutant Htt expression (Figure 15A, lower graph).  
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Figure 15: Impaired cell viability and aconitase activity as a result of exon1-Q72 expression in 
differentiated HN10 cells. A: Induction of exon1-72Q expression in proliferating (upper graph) and 
differentiating cells (lower graph) leads to decreased cell viability as measured by cellular protein expression 
levels only in differentiating cells. B: Aconitase activity as a measure for mitochondrial function and presence of 
radical oxygen species reveals impaired mitochondria function after 3 days of exon1-72Q expression in 
differentiated but not proliferating cells. (All graphs: n=4, p<0.05=*, p<0.01=**). 
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Since PGC1-alpha, a key regulator of mitochondriogenesis, was downregulated in 
proliferating and in differentiated cells upon exon1-72Q expression but only differentiated 
cells displayed a significant impairment in cell viability, we examined the influence of exon1-
72Q expression on mitochondria in noninduced and induced cells under proliferating and 
differentiating conditions. Using aconitase activity as a marker for mitochondrial function and 
oxidative damage (Bulteau et al., 2003; Gardner et al., 1994; Yan et al., 1997), we found a 
significant mitochondrial impairment in differentiating cells after 3 days of exon1-72Q 
expression (Figure 15B, lower graph) but not in proliferating cells (Figure 15B, upper graph) 
when compared to noninduced control. 
To validate that the observed effects of exon1-72Q in differentiated cells are a direct result of 
the mutated polyQ stretch in the exon1 fragment and not due to the expression of a Htt 
fragment per se, we compared the effects of wild-type exon1-25Q and mutant exon1-72Q 
expression on cell viability (Figure 16). Measuring caspase 3/7 activity as a generic marker 
for apoptosis showed an increased caspase activity in differentiated cells upon exon1-72Q 
expression whereas expression of the wild-type exon1-25Q fragment resulted in decreased 
caspase 3/7 activity (Figure 16A). Using neurite outgrowth as an orthogonal readout for the 
different effects of wild-type and mutant huntingtin fragments in differentiating cells verified 
the protective effect of exon1-25Q expression whereas expression of exon1-72Q construct 
resulted in a significantly decreased neurite outgrowth (Figure 16B). 
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Figure 16: Effects of wild-type and mutant huntingtin exon1 expression on cell viability in differentiated 
cells. A: Caspase 3/7 activity as a measure of cellular dysfunction reveals increased apoptosis after exon1-72Q 
expression in differentiated cells. Expression of the wild-type construct exon1-25Q protects the differentiated 
cells from caspase 3/7 activity. B: Quantification of tubulin/nuclei ratio with in-cell western as a indicator for 
neurite outgrowth in differentiated HN10 clones upon exon1-25Q or exon1-72Q induction. Induced expression 
of wild-type exon1-25Q leads to increased neurite outgrowth over noninduced control whereas expression of 
mutant exon1-72Q construct leads to decreased neurite formation. (A: n=4, B: n=3, All graphs: p<0.05=*, 
p<0.01=**). 
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4.1.5 DISCUSSION 
Despite a remarkable progress in the understanding of HD, the most common monocausal 
neurodegenerative disorder (Bates et al., 2002), over the past decades, the cellular mechanisms 
leading to neuronal death remain elusive and various pathogenic mechanisms of action have 
been proposed including transcriptional dysregulation, impaired neurite function and 
mitochondrial dysfunction. In order to elucidate some of the open questions concerning the 
pathology of Huntington’s Disease and to establish a valid cellular Huntington’s Disease 
model which can be used for drug discovery purposes, we have developed a flexible 
expression system in a neuronal cell line in which we can control the amount and time of 
wild-type and mutant Htt expression (Figure 12) as well as the mitotic state of the cells 
(Figure 13).  
The ability to culture the cells under both proliferating as well differentiating conditions is 
especially relevant considering that terminally differentiated cells such as neurons and adult 
muscle cells display the strongest aggregate formation and are most vulnerable to mutant 
huntingtin expression (Arenas et al., 1998; Fennema-Notestine et al., 2004; Lodi et al., 2000; 
Rosas et al., 2003; Sathasivam et al., 1999b). Since the rate of aggregation is dependent on the 
intracellular concentration of mutant huntingtin fragments (Scherzinger et al., 1999), the 
increased aggregate formation in these cell types is thought to be a direct result of their 
terminally differentiated status in which a threshold concentration of aggregation-prone 
mutant huntingtin precursors can be surpassed. In contrast, the continuous division of 
proliferating cells allows for a constant dilution of the cleaved mutant huntingtin fragments 
therefore making it more unlikely that the amount of intracellular huntingtin fragments can 
built up to a critical concentration. Indeed when comparing the effects of induced mutant 
huntingtin expression in the identical clone line which has been either cultured under 
proliferating or differentiating conditions, a different susceptibility to the mutant huntingtin 
became apparent with differentiating, post-mitotic cells being more vulnerable to the toxic 
insult from mutant huntingtin than the mitocically active proliferating cells (Figure 15). 
By comparing the effects of exon1-25Q and exon1-72Q expression on cell viability, we 
showed that the sensitivity of differentiated HN10 cells to mutated huntingtin fragment is 
specific to the elongated polyglutamine stretch in the huntingtin fragment and not to the 
artificial expression of a short huntingtin fragment itself (Figure 16). Interestingly, the 
expression of a wild-type huntingtin fragment resulted in a protective effect on caspase 3 
activity, a finding which is in agreement with earlier in vitro and in vivo Huntington’s Disease 
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models (Leavitt et al., 2006; Rigamonti et al., 2000; Rigamonti et al., 2001) thus further 
validating the applicability of our inducible neuronal cells as a Huntington’s Disease model.  
Some open questions which may limit the use of our model for Huntington’s Disease research 
remain. Even though the toxic effect of mutant huntingtin expression on the cells has been 
verified with three orthogonal readouts (cellular protein levels, caspase activity and neurite 
outgrowth), none of these readouts examines a specific cellular pathway. Therefore in theory, 
it may be possible that the observed impairments in cell viability in our inducible neuronal 
clones are unrelated to the pathologic biological mechanism of action occurring in patients. 
While expression of aminoterminal mutated fragments results in a more aggressive toxicity 
and allows for an increased dynamic range of our readouts, this decision prevents our model 
from being used to answer biological questions that may require the expression of more 
carboxyterminal parts of the mutated huntingtin protein. For example, cellular pathways 
relevant for the development of Huntington’s Disease that may interact specifically with 
huntingtin’s nuclear export signal at the carboxyterminus (Xia et al., 2003) cannot be studied 
with our current setup. Hence, further studies should include the development of an inducible 
full length mutant huntingtin clone based on our neuronal model system as well as the more 
in-depth analysis of specific cellular pathways that are supposed to be affected in 
Huntington’s Disease.  
Nevertheless, the current data supports the applicability of our neuronal cells as a valid model 
for Huntington’s Disease. Induced expression of mutated huntingtin fragment results in 
prominent cellular defects also found in patients such as aggregation of mutated huntingtin 
fragments, specific transcriptional dysregulation, impairment of cell viability and 
mitochondrial dysfunction. Future use of our cell model will therefore include pathway 
analysis of the toxic mechanisms of action and identification of compounds which may 
ameliorate the described effects resulting from mutant huntingtin expression. 
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4.2.1 SUMMARY 
A CAG repeat gene expansion translated into a pathogenic polyglutamine stretch at the N-
terminus of huntingtin triggers Huntington's Disease. Mutated huntingtin is predicted to adopt 
toxic properties mainly if aggregation-prone N-terminal fragments are released by proteolysis. 
Huntingtin-aggregates are indeed a major hallmark of this disorder and could represent useful 
markers of disease-onset or progression. We designed a simple method for qualitative and 
quantitative characterization of aggregates. For this, we analyzed samples from in vitro and in 
vivo Huntington’s Disease models by agarose gel electrophoresis and show that in the brain of 
transgenic mice huntingtin-aggregates became larger as a function of disease progression. 
This appears to be a property of cytoplasmic but not nuclear aggregates. In cell cultures, 
treatment with Congo Red inhibited aggregate growth but not total load. Finally, we show that 
in primary striatal neurons and in brains of R6/2 and HdhQ150 mice, the presence of 
aggregates preceded initiation of any other functional deficits. This observation argues for a 
pathogenic role of huntingtin-aggregation in Huntington`s Disease. Our results emphasize that 
thorough analysis of huntingtin metabolism and aggregation is now feasible, thus significantly 
improving the power of studies assessing therapies designed to lower huntingtin levels or to 
interfere with its aggregation. 
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4.2.2 INTRODUCTION 
Huntington’s Disease (HD) is a neurodegenerative disorder characterized by motor 
dysfunction (choreiform movements), emotional disturbance, dementia, and weight loss 
(Bates et al., 2002). HD is caused by an autosomal dominant expansion of a CAG repeat 
encoding for polyglutamine (polyQ) in exon 1 of the huntingtin (Htt) gene (Group, 1993b). 
Mutated Htt (mHtt) gains a neurotoxic function, leading to the onset of clinical symptoms 
mostly in mid-life. The progression of HD is characterized by a marked degeneration of gray 
and white brain matter whereby a loss of vulnerable neurons, most notably striatal medium-
sized spiny neurons, is observed, while resistant populations are spared (Davies et al., 1997; 
DiFiglia et al., 1997; Henley et al., 2006; Rosas et al., 2006; Ruocco et al., 2006; Vonsattel 
and DiFiglia, 1998). HD progresses relentlessly with a lethal outcome about two decades after 
diagnosis.  
In transgenic mouse models of HD the expression of N-terminal fragments or full-length mHtt 
leads to HD-like pathology and associated motor, cognitive and behavioral deficits. R6/2 mice 
are the first and most intensely studied mouse model of HD (Mangiarini et al., 1996). They 
express mHtt-exon 1 with an expansion of more than 150 glutamines under the control of the 
human Htt-promoter. The mice develop an early and severe phenotype with first motor 
deficits appearing already at 5-6 weeks (wk) after birth, behavioral deficits are observed at 8 
wk and rapid lethality ensues after 14 wk of age. Because of this fast and prominent 
progression, R6/2 mice are often used to dissect the neurodegenerative processes causing HD 
or as a translational model for experimental therapeutics. Critically, neuronal dysfunction can 
be replicated in vitro by expressing N-terminal fragments of mHtt in cell lines and primary 
neuronal cultures (Li et al., 2000; Saudou et al., 1998). 
A hallmark of neuropathology in animal HD models as well as in human patients affected by 
HD is the presence of intracellular mHtt-aggregates (Davies et al., 1997; Nguyen et al., 2006; 
van Roon-Mom et al., 2002; Woodman et al., 2007). It is an ongoing debate whether these 
mHtt containing aggregates are toxic to the cell, neutral byproducts of the pathogenic process 
or even neuroprotective by sequestering toxic polymeric forms of mHtt (Chen et al., 2001; 
Davies et al., 1997; DiFiglia et al., 1997; Yang et al., 2002). Even though the exact role of 
mHtt-aggregates in HD pathology remains unclear, it is a common observation that 
accumulation of aggregates in brains of HD patients and animal models increases with disease 
progression (DiFiglia et al., 1997; Gutekunst et al., 1999; Menalled et al., 2003; van Roon-
Mom et al., 2002; Woodman et al., 2007). In R6/2 mice, histochemistry was used to show 
wide-spread accumulation of Htt in cytosolic and nuclear inclusions, which increased in 
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number and size with age and whose formation was highly correlated with the progression of 
neurological symptoms (Li et al., 1999). In light of these findings, detailed and sensitive 
mHtt-aggregate characterization is therefore required when analyzing disease onset and 
progression or for testing disease-modifying treatments. 
As discussed, histochemistry provides access to the study of aggregate morphology, number 
and regional localization but does not provide the power for quantitative biochemical 
determinations. PolyQ-aggregates are insoluble and resistant to chemical extractions, thus 
they can be poorly determined by polyacrylamide gel electrophoresis because they are 
retained in the loading wells (Hazeki et al., 2000). More precise biochemical quantitative 
information can be obtained with the filter-trap assay for aggregates (Scherzinger et al., 1997). 
However, detailed investigation of aggregate growth or of aggregate composition depending 
on size is impossible by this method due to indiscriminate retention of all protein inclusions 
larger than the filter pores of the cellulose acetate membrane. 
Here, we developed Agarose Gel Electrophoresis for Resolving Aggregates (AGERA) as a 
simple and sensitive biochemical detection method for quantitative and qualitative 
investigations of aggregate formation in in vitro and in vivo HD models. Notably, using 
AGERA we report that sizeable amounts of aggregates are found before the onset of other 
pathological dysfunctions in different in vitro and in vivo models of HD suggesting a 
pathogenic role of aggregates in HD. 
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4.2.3 MATERIALS AND METHODS 
Cell culture, DNA transfections and lentivirus infections 
HN10 cells were grown in DMEM (Gibco), 10% FCS, penicillin and streptomycin. Plasmid 
transfections were performed with Lipofectamine 2000 (Invitrogen) according to the 
manufacturer protocol. Two days later, cells were lysed in RIPA buffer (10 mM Tris pH 7.5, 
150 mM NaCl, 1 mM EDTA pH 8, 1% NP40, 0.5% SDS, Complete Protease Inhibitor) and 
samples were separated by electrophoresis on agarose or SDS polyacrylamide gels (Wiltfang 
et al., 1991). For immunohistochemistry, cells were fixed with 4% paraformaldehyde (PFA) 
and GFP autofluorescence was analyzed by microscopy.  
Primary striatal cultures were prepared and cultured as described (Zafra et al., 1990). In short, 
timed-pregnant female mice were sacrificed and embryos were collected at E16.5. Ganglionic 
eminences were dissected and incubated for 20 min at 37°C in phosphate buffered saline 
(PBS) without Ca2+/Mg2+ (Gibco), but containing 10 mM glucose, 1 mg/ml albumin (Sigma), 
6 g/ml DNase (Sigma) and 0.25% trypsin (Sigma). After washing, striatal cells were 
dissociated with a fire polished Pasteur pipette. Cells were collected and resuspended in 
DMEM (Gibco), supplemented with 10% FCS and plated on culture dishes precoated with 
poly-DL-ornithine (0.5 mg/ml) and  cultured in serum-free medium and supplements (Brewer 
and Cotman, 1989). One day after plating, cells were infected with lentivirus expressing Htt-
exon1 with 25Q or 72Q. A virus expressing eGFP was used as control, generation and titer 
determination were done as previously described (Regulier et al., 2004). Briefly, 293T cells 
were transfected with four plasmids encoding for packaging proteins, envelope (VSV-G) 
protein, Rev protein and transfer vector encoding for Ex1-25Q, Ex1-72Q or GFP proteins. 
The viruses were resuspended in (PBS) with 1% BSA and matched for particle content in ng 
p24 antigen/ml as measured by ELISA (Zeptometrix Corp; USA). The cell cultures were 
infected with lentiviral vectors at ratio of 100 ng of p24 antigen/105 cells the day after plating 
(1 DIV). 
Four and seven days after infections, cells were either lysed and analyzed by gel 
electrophoresis or fixed with 4% PFA and stained with mEM48 antibody (Chemicon, MAB 
5374) and DAPI according to standard immunohistochemistry protocol.  
 
Generation and characterization of inducible HN10 cell line 
Rheoswitch system (New England Biolabs) was used to create a stable HN10 cell line with 
inducible Ex1-72Q expression. Ex1-Q72 was subcloned into the pNEBR-X1Hygro Vector 
according to standard molecular biology procedures. HN10 cells were transfected with 
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pNEBR-R1 plasmid and cultured with 1 mg/ml G418 (Invitrogen). Stable clones were first 
screened for normal cell morphology, transiently transfected with the pNEBR-GLuciferase 
reporter plasmid and induced with 500 nM Rheoswitch-ligand (RSL). Luciferase expression 
was measured and the clone with highest induction ratio was further expanded and 
subsequently transfected with pNEBR-ExQ72 plasmid. Stable clones were selected with 1 
mg/ml G418 and 1 mg/ml Hygromycin (Invitrogen) and screened for normal cell morphology. 
Expression of Ex1Q72 in stable clones was monitored after induction with 500 nM RSL. 
Expression levels were analyzed with western blot. The clone with the best expression level 
and non detectable basal expression was chosen for further experiments (HN10-Ex1Q72V). 
For RSL-concentration and time-dependency of induction, HN10-Ex1Q72V clone was grown 
in RSL-containing media as indicated. Cell lysates were analyzed by western blot for 
huntingtin monomer expression or AGERA for aggregate determination. 
 
Brain homogenates and subcellular fractionation 
Aggregate quantification was conducted using mouse brains homogenized in 10 volumes 
(w/v) TBS (100 mM Tris, pH 7.4, 150 mM NaCl) and Complete Protease Inhibitor (Roche 
Diagnostics) twice for 2 min at 30 Hz in a Retsch MM 300 Mill. Samples were further 
homogenized by 10 ultrasound pulses with a Branson sonifier and stored at -80°C. 
To isolate cytoplasmic and nuclear fractions, each brain was homogenized in 5 volumes (w/v) 
ice-cold Buffer 1 (575 mM sucrose, 25 mM KCl, 50 mM triethanolamine, 5 mM MgCl2, 1 
mM DTT, 0.5 mM PMSF, Complete Protease Inhibitor) and few strokes with Teflon pestle in 
a glass homogenizer. DTT concentration was adjusted to 5 mM. A crude homogenate aliquot 
was kept as starting material reference. The rest of the homogenate was centrifuged at 800 g 
for 15 min (all centrifugations were run at 4°C) to isolate a crude nuclear fraction (pellet) and 
a cytoplasmic fraction (supernatant). The nuclei were resuspended in Buffer 1 to 3 ml final 
volume and supplemented with 6 ml of Buffer 2 (2.3 M sucrose, 25 mM KCl, 50 mM 
triethanolamine, 5 mM MgCl2, 1 mM DTT, 0.5 mM PMSF, Complete Protease Inhibitor) and 
centrifuged at 124,000 g for 1 h over a cushion made of 0.5 ml Buffer 2. The pellet was 
resuspended in 500 µl Buffer 1 and centrifuged at 800 g for 15 min. The nuclear fraction was 
equivalent to the pellet dissolved in 100 µl 1% SDS in PBS and boiled for 10 min to shred the 
DNA. For different mice, samples were normalized after immunoblots with antibodies to α-
tubulin or histone 1, marker proteins for the cytoplasmic and nuclear fractions, respectively. 
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Filter-trap retardation assay 
Brain homogenate samples were diluted 1:10 v/v with 250 µl 2% SDS in PBS, corresponding 
to 0.15 mg of total protein per brain tissue sample. Cellulose acetate membrane (Whatman 
Group, OE 66, 200 nm pore size) was equilibrated in 2% SDS in PBS and samples where 
sucked through the membrane on a Biorad dot-blot vacuum device. Wells were washed three 
times with 300 µl 2% SDS in PBS. Membrane was blocked with 10% milk powder in TBS for 
1 h and incubated with primary antibody overnight at 4°C. The antibodies were selective for 
ubiquitin (1:5000; DAKO) or for Htt (1:1000, MW1 and MW8 (Ko et al., 2001), Chemicon 
mEM48/MAB5374 and Nov1). Nov1 mouse monoclonal antibody was generated by custom 
production (GENOVAC GmbH, Germany) after DNA-vaccination with a cDNA encoding for 
Q25Htt1-857. The membranes were washed three times with TBST and incubated with 
secondary antibody (1:10000, anti-mouse or anti-rabbit IgG coupled to horse radish 
peroxidase). After washing, immunoblots were developed with the ECL detection reagent 
(Amersham Biosciences). The MCID software was used for densitometric analysis of 
digitalized autoradiograms.  
 
AGERA 
For short 1.5% (2%) agarose gels, 1.5 g (2 g) agarose (Biorad, #161-3101) was dissolved in 
100 ml 375 mM Tris-HCl, pH 8.8 brought to boiling in a microwave oven. After melting, 
SDS was added to a final concentration of 0.1%. Gels were poured on short Biorad DNA Sub 
CellTM trays resulting in a gel thickness of 8 mm. Long 1% (1.5%) agarose gels were obtained 
by dissolving 2.5 g (3.75 g) agarose in 250 ml 375 mM Tris-HCl, pH 8.8, adjusting the final 
SDS concentration to 0.1% and pouring the gels on long Biorad DNA Sub CellTM trays (gel 
thickness = 8 mm). Samples were diluted 1:1 into non-reducing Laemmli sample buffer (150 
mM Tris-HCl pH 6.8, 33% glycerol, 1.2% SDS and bromophenol blue) and incubated for 5 
min at 95°C. For brain tissue samples, 0.15 mg of total protein, for cellular samples 0.1 mg of 
total protein was loaded per AGERA lane. Purified catalase (232 kDa), ferritin (440 kDa) and 
thyroglobulin (669 kDa) were taken as high molecular weight size markers (all proteins 
included in Amersham Bioscience HMW Gel Filtration Kit, #17-0441-01). After loading, gels 
were run in Laemmli running buffer (192 mM glycine, 25 mM Tris-base, 0.1% SDS) at 100 V, 
2 A until the bromophenol blue running front reached the bottom of the gel. Semi-dry 
electroblotter model B (Ancos) was used to blot the gels on PDVF membranes (Millipore 
Immobilon-P, #IPVH00010) at 200 mA for 1 h with a Biorad 200 power supply (transfer 
buffer: 192 mM glycine, 25 mM Tris-base, 0.1% SDS, 15% methanol). As the thickness of 
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the 1% long gels decreased substantially during the 1 h transfer, a 500 g weight was centered 
on the electroblotter’s top to guarantee constant and even contact between the gel and the 
electroblotter when blotting these gels. After transfer, starting with the blocking step, 
immunoblot membranes were then developed exactly as described for the cellulose acetate 
membranes. 
 
Aggregate analysis  
To determine the relative mHtt-aggregate size, AGERA autoradiograms were digitalized with 
a Cool Snap Photometrics camera. Densitometry of aggregate signals was performed with 
MCID software. The peak signal intensity for each lane and the distance of this peak signal to 
the running front were calculated automatically with MCID. For each experiment, the largest 
peak distance, which represented the lane with the largest aggregates, was set to 1. 
 
Immunoprecipitations 
30 µl brain homogenate from 14 wk-old R6/2 mice was diluted in 950 µl RIPA buffer. 2 µg 
ubiquitin- or huntingtin antibodies were added and incubated on a shaker at 4°C overnight. 15 
µl Protein A/G bead mixture (1:1) was added and incubated at 4°C for 2 h. Beads were 
washed three times with RIPA buffer. 30 µl Laemmli sample buffer was added and the beads 
were incubated for 10 min at 95°C. Supernatants were then loaded on 1.5% agarose gels, 
immunoblotted and analyzed with anti-ubiquitin antibody. 
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4.2.4 RESULTS 
AGERA is a sensitive assay to visualize and quantify mHtt-aggregates  
The formation of mHtt containing aggregates is one of the major hallmarks of HD. The 
prevention of the formation of these aggregates in neurons may represent an attractive 
therapeutic strategy to ameliorate Huntington's disease. A sensitive and quantitative method is 
necessary to monitor aggregate formation and progression or when assessing the efficacy of a 
potential drug candidate against HD. So far the analysis of the onset and progression of Htt-
aggregates in biological samples has relied on immunohistochemistry or the filter-trap 
retardation assay, a method that has analytical limitations due to its all-or-nothing cut-off 
imposed by the size of the membrane pores. We thus designed an agarose gel electrophoresis-
based methodology enabling the quantitative and qualitative investigation of Htt-aggregation 
with high sensitivity and generating reliable values. We applied this Agarose Gel 
Electrophoresis for Resolving Aggregates (AGERA) to determine the load of mHtt-aggregates 
in the brain of 14 wk-old R6/2 mice, which display pronounced Htt-deposition and brain 
pathology. At 14 wk of age, R6/2 mice suffer of severe HD-like symptoms approaching the 
terminal stage. The presence of Htt-inclusions in the R6/2 brain extracts was first verified by 
the filter-trap assay (Figure 17A, upper panels) using three different Htt-specific antibodies as 
well as an anti-ubiquitin antibody, confirming previous findings that the presence of ubiquitin 
is a hallmark of Htt-aggregates in R6/2 mice (Davies et al., 1997). A weak but discernible 
background signal was present for all used antibodies also in brain samples from wild-type 
(wt) littermate controls. The same samples were then resolved using AGERA (Figure 17A, 
lower panels) and the dynamic range of this method was assessed by comparing the signal 
intensity obtained for the 14 wk-old R6/2 mice with that of wt mice. When compared to the 
filter-trap assay, the signal-to-background ratios were considerably improved by AGERA 
(Figure 17B). In fact, the mean ratio determined by AGERA was 340-fold over background 
and thus 18-fold larger than that produced by the filter-trap assay (each group n=6). On the 
AGERA immunoblots, aggregates were detected with Htt antibodies as well as with the 
ubiquitin antibody (Figure 17A, lower panel).  
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Figure 17: A: Identical samples of brain homogenates from 14 wk-old R6/2 mice or wt siblings were analyzed 
by filter-trap retardation assay or by AGERA on short 2% agarose gels. Both methods visualize aggregates with 
antibodies against huntingtin (MW8, EM48, Nov1) or ubiquitin in the transgenic but not in the wt samples. B: 
Comparison of the sensitivity of AGERA with the filter-trap assay. Signal ratios were calculated using the 
respective mean background signal obtained for brains of age-matched wt siblings and are shown with error bars 
representing standard deviations. AGERA generates a signal 340-fold ± 75 above background in 14 wk-old R6/2 
brains compared to a 19-fold ± 10 signal using the filter-trap retardation assay (n=6; ***=p<0.001). 
 
In order to demonstrate that the ubiquitin signal detected in brains of 14 wk-old R6/2 mice 
resulted from Htt-ubiquitination, a brain homogenate sample was first immunoprecipitated 
with the MW8 antibody specific for huntingtin or with the anti-ubiquitin antibody and then 
analyzed by ubiquitin-immunoblotting (Figure 18).  
 
Figure 18: Htt-aggregates in brain homogenate of 14 wk-old R6/2 mice were immunoprecipitated with 
huntingtin antibody (MW8) or ubiquitin antibody (Ubi). Detection of aggregates on AGERA blots with ubiquitin 
antibody shows that huntingtin aggregates are ubiquitinated. 
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Although we can not exclude that other ubiquitinated proteins were sequestered into the 
aggregates, these data support the view that mHtt-aggregates were indeed ubiquitinated and 
that, more importantly, AGERA can reveal the extent of ubiquitination, and possibly other 
posttranslational modifications, of Htt-aggregates in biological samples. 
 
Separation of mHtt-aggregates by AGERA is based on their size 
Htt-aggregates resolved by AGERA were distributed over a wide region of the gel. We 
analyzed whether the signal smear was caused by the presence of heterogeneous species of 
inclusions or due to the low resolving property of the gels. For this, brain homogenates of 14 
wk-old R6/2 mice were first separated by agarose gel electrophoresis to obtain multiple gel 
fractions depending on their mobility on the gel. The fractions were then embedded in a 
second gel and again resolved by electrophoresis. We found that, as an example, Htt-
aggregates isolated from the middle part of the gel retained a similar migration behavior when 
analyzed by AGERA and were separated from Htt-aggregates isolated from the upper or 
lower ends of the gel (Figure 19A). Thus, we concluded that AGERA resolved distinct, 
heterogeneous species of aggregates over most of the length of the gel. Supporting these data, 
another sample of a 14 wk-old R6/2 mice was run in two perpendicular dimensions of the 
agarose gel. This resulted in a 2D spatial resolution of the Htt-aggregates. The signal 
distributed mainly along the gel diagonal (Figure 19B) confirming that AGERA is a method 
suitable to separate distinct Htt-aggregate species in a reproducible manner.  
 
Figure 19: A: Two samples from a brain homogenate from a 14 wk-old R6/2 mouse were resolved by AGERA. 
The first sample was immunoblotted using the MW8 antibody (I). For the second sample, five sections were 
dissected from the agarose gel, embedded into a new gel and resolved again by AGERA (II). Aggregates 
preserve a distinct migration rate on the second gel, suggesting that Htt-aggregates are specifically and 
reproducibly separated in the agarose gels according to their size. B: A brain homogenate from a 14 wk-old R6/2 
mouse was run on a short 1.5% agarose gel. The entire lane was dissected, embedded in a perpendicular direction 
in a new agarose gel and resolved by electrophoresis. Detection of the Htt-aggregates transferred on a PVDF 
membrane using MW8 reveals the two-dimensional distribution mostly along the diagonal of the second agarose 
gel. This indicates that separation by AGERA is reproducible and based on a heterogeneous trait of Htt-
aggregates. 
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Htt-aggregate formation in HN10 cells 
To analyze the formation of Htt-aggregates in vitro, we first transiently expressed Htt-exon 1 
fused to green fluorescent protein (GFP) with either 72 (Ex1-Q72GFP) or 25 glutamines 
(Ex1-Q25GFP) in HN10 neuroblastoma cells (Lee et al., 1990). Ex1-Q25GFP, a construct 
with a non-pathologic polyQ-length, was distributed diffusely throughout the cytosol as 
indicated by GFP-autofluorescence. Ex1-Q72GFP, a construct similar to the ones routinely 
used to study the aggregation-prone effect of elongated polyQ-repeat in Htt (Bodner et al., 
2006; Lecerf et al., 2001; Zhang et al., 2005) formed aggregates which were located in the 
nucleus (Figure 20A). Equal expression of monomeric Htt was verified by polyacrylamide gel 
electrophoresis (Figure 20B, SDS-PAGE) and the presence of Htt-aggregates in Ex1-Q72GFP 
transfected cells was verified by the filter trap assay and AGERA (Figure 20B). No aggregates 
were detected in mock transfected cells or in cells transfected with Ex1-Q25GFP. On the other 
hand, aggregates were visualized with anti-Htt antibodies (Figure 20B, AGERA) or anti-GFP 
antibodies (not shown) in Ex1-Q72GFP transfected cell lysates. The mEM48 and Nov1 
antibodies specific for soluble and aggregated Htt detected both forms of the protein by 
AGERA. In contrast, MW1 an antibody specific for monomeric, soluble Htt (Ko et al., 2001), 
failed to detect Htt-aggregates in Ex1-Q72GFP transfected cell lysates, but visualized 
monomers running just behind the running front of the agarose gel and which were poorly, if 
at all, retained by the filter-trap retardation assay. These data confirm the potential of AGERA 
to separate and detect in a single step soluble and aggregated Htt forms present in cells 
expressing mutant Htt in vitro. 
 
Figure 20: A: HN10 neuronal cells were transiently transfected with huntingtin Ex1-Q25GFP or Ex1-Q72GFP 
plasmids and analyzed after 2 days by GFP autofluorescence. Huntingtin Ex1-Q72GFP forms aggregates located 
predominantly in the nucleus, whereas Ex1-Q25GFP distributed evenly in the cytoplasma of the cells B: 
Identical amounts of lysates from HN10-cells transfected with Ex1-Q72GFP, Ex1-Q25GFP or with empty vector 
(mock) were analyzed by filter-trap, by AGERA on short 2% agarose gels or by SDS-PAGE as indicated on the 
left of the panels. SDS-PAGE confirms equal expression of the Htt constructs with three Htt-antibodies. 
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Aggregates in cells expressing the pathogenic Ex1-Q72GFP construct were detected selectively with Htt-specific 
antibodies. Ex1-Q25GFP-monomers running just behind the running front of the agarose gel reacted also to the 
MW1 antibody. 
 
Congo Red affects the size, not the amount, of Htt-aggregates in vitro 
The dye Congo Red stains protein aggregates in various neurodegenerative diseases by 
binding to fibril proteins with enriched β-sheet conformation (Divry, 1927; Frid et al., 2007). 
Recent in vitro and in vivo studies in HD models indicate that Congo Red treatment prevents 
later stages of mHtt-fibrillization into larger aggregates (Poirier et al., 2002), thereby reducing 
mHtt- accumulation in general (Heiser et al., 2000; Sanchez et al., 2003; Smith et al., 2001). 
In order to study a possible effect of Congo Red, or other chemical compounds, on the 
formation of mHtt-aggregate in vitro, we created a stable HN10 clone with inducible Ex1-Q72 
expression in the absence of the GFP or any other tags (Figure 21A,B). In this cell line, Htt-
aggregates were detected as early as 3 days after induction (Figure 21C). Similar data were 
obtained with independent cell clones but not with inducible cell lines for normal polyQ-
length (Ex1-Q25; data not shown). 
 
Figure 21: A: Monomer expression of Ex1-Q72 in HN10-Ex1Q72V clone was induced by adding different 
Rheoswitch-ligand (RSL) concentrations to the culture media. Cells were lysed after 3 days of induction and 
monomer expression levels were analyzed with anti-huntingtin antibody EM48 on a western blot. B: Monomer 
expression of Ex1-Q72 in HN10-Ex1Q72V clone was induced by adding 500 nM RSL to the culture media. 
Cells were lysed 0-7 days after induction and monomer expression levels were analyzed with anti-huntingtin 
antibody EM48 on a western blot. C: Expression of Ex1-Q72 was induced in HN10-Ex1Q72V clone by adding 
500 nM RSL to the culture media. Cells were lysed after 0, 3 or 6 days of induction and equal protein levels of 
cell lysates were analyzed with AGERA to visualize aggregate load 
 
nM RSL
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Interestingly, treatment with increasing amounts of Congo Red caused the Htt-aggregates to 
acquire a faster mobility on the AGERA gels, indicative for decreased size of the aggregates 
in the presence of Congo Red (Figure 22, AGERA blot). Quantification of this effect was 
obtained by measuring the position of the peak signal intensity within the gel lane in relation 
to its distance from the running front (Figure 22, bar graph).  
 
 
Figure 22: Congo Red treatment (up to 40 µM) of an induced Ex1-Q72 expressing HN10 clone inhibits 
aggregate growth as visualized by AGERA on short 1.5% agarose gels (left panel) or quantified as relative 
apparent mobility (right panel) using densitometric scans of the gels (n=3;*=p<0.05, **=p<0.01). 
 
The dose-dependent effect of Congo Red culminated at the maximal concentration tested (40 
µM), whereby the peak aggregate size was reduced to a relative factor of 0.76 when compared 
to the vehicle control (value set to 1). Due to logarithmic dependence of Rf on molecular 
weight, the difference on Htt aggregate size after Congo Red treatment may even be bigger. 
Nevertheless, a precise determination of the Rf values on AGERA is difficult due to the 
paucity of adequate markers for the molecular weight range of aggregates. Our data are in 
good agreement with the effect of Congo Red on Htt aggregation reported using the filter-trap 
retardation assay (Heiser et al., 2000) but demonstrate that this effect did not relate to the total 
load of aggregates present in the cells. This was rather due to a change in the aggregate type in 
favor of smaller species, which may have escaped detection in the filter-trap assay.  
 
Htt-aggregates in striatal primary cells precede appearance of polyQ-induced toxicity  
To extend our studies to a cellular model more relevant to HD, we infected primary striatal 
cells with a lentivirus transducing expression of Ex1-Q25 or Ex1-Q72 in the absence of the 
GFP-tag. As previously described (Zala et al., 2005) and using GFP-transduction as control, 
stable and sustained expression of the transgene was observed in more than 90% of the 
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cultured neurons with no sign of cytotoxicity at the viral dose used (data not shown). The 
same conditions were used to transduce striatal primary neurons with Ex1-25Q or Ex1-72Q. 
Immunocytochemistry using the mEM48 antibody revealed aggregates in most if not all 
nuclei of Ex1-Q72 infected striatal cells 7 days after infection. In contrast, the Ex1-Q25 
construct was evenly distributed in the cytosol of cell bodies and neurites of the neurons 
(Figure 23).  
 
 
Figure 23: Striatal primary cells were infected with a lentivirus driving expression of Ex1-Q25 or Ex1-Q72. 
After seven days of infection the cells were fixed and stained with the mEM48 antibody. The Ex1-Q25 protein 
distributes in the cytoplasma and neurites whereas the Ex1-Q72 Htt fragment localizes to the nucleus and formed 
aggregates. 
 
Consistent with previously published data (Li et al., 2000; Saudou et al., 1998; Zala et al., 
2005), severe neuron degeneration and neurite collapse were observed at 7 days after infection 
for neurons expressing Ex1-Q72 but not for cells expressing Ex1Q25 or GFP (Figure 24).  
 
 
Figure 24: Light microscopy of transduced striatal cells 7 days after transfection reveals severe 
neurodegeneration in cells infected with Ex1-Q72 but not in cells infected with Ex1-Q25.  
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More relevantly, significant amounts of Htt-aggregates were already detected at 4 days post-
transduction in lysates of Ex1-Q72 expressing primary striatal cells, thus well before the onset 
of visible neurite degeneration (Figure 25).  
 
 
Figure 25: Lysates of transduced cells were analyzed by AGERA on short 1.5% agarose gels or SDS-PAGE. 
EM48 antibody detects Htt-monomers after SDS-PAGE and aggregates by AGERA in the Ex-1Q72 infected 
cells at 4 and 7 days post-infection. The data were reproduced in at least three independent experiments. 
 
The load of aggregates increased further at the 7th day of infection. As expected, no Htt-
aggregates or toxicity were detected in striatal neurons transduced with GFP or Ex1-Q25, 
despite the presence of huntingtin monomers at 4 and 7 days after infection (Figure 25; SDS-
PAGE). Quantification of the partition of monomeric mHtt (detected after SDS PAGE) versus 
aggregated mHtt (detected by AGERA) demonstrated an increase of Ex1-Q72 aggregates 
between day 4 and 7 post-infection accompanied by a reduction in the amount of monomeric 
Htt (not shown). 
 
Presence of presymptomatic Htt-aggregates in mouse models of HD 
Having demonstrated biochemically that Htt-aggregate formation occurred before or at the 
onset of neurodegeneration in a cellular model of HD, we proceeded to study Htt-aggregate 
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appearance in two mouse models of HD. Using AGERA, we detected a significant amount of 
Htt-aggregates in brains of R6/2 mice already at 2 weeks after birth (Figure 26). At this age, 
no behavioral differences were detectable when we compared R6/2 mice to littermate controls 
(data not shown and (Davies et al., 1997; Li et al., 1999)).  
 
 
Figure 26: Onset and accumulation of aggregated Htt as a function of age were assessed in brain homogenates 
from 2, 4, 6 and 8 wk-old wt or R6/2 mice. Data are shown as signal ratios over background with error bars 
representing standard deviations (n=6-8; *** = p<0.001).  
 
The aggregate signal by AGERA was 6-fold higher than that determined in age-matched wt 
siblings (p <0.001, each group n=6). Accumulation of Htt-aggregates progressed in a semi-
exponential modus across the age groups 4 wk (8.6-fold above controls, p <0.001), 6 wk (24-
fold, p <0.001) and 8 wk (90-fold, p <0.001) (Figure 26). Maximal aggregate load was 
measured in the 14 wk-old R6/2 mice (340-fold, Figure 17B). In contrast, when analyzing the 
homogenates with filter trap assay, no aggregate signal was detected at 2 wk and the signal at 
4 wk was 3.3-fold (p <0.05) above background (data not shown). To assess the potential of 
AGERA to detect a difference in Htt-accumulation over a period of 2 wk (a typical treatment 
duration for subchronic drug trials), we conducted a power analysis using the values acquired 
at 4 and 6 wk of age. Under these conditions, a 30% reduction in the amount of Htt-
aggregates accumulating over this period is predicted to be observed at 95% confidence (p = 
0.05) with 10 transgenic mice per treatment arm (20% reduction would require group sizes of 
at least 22 animals, 40% reduction group sizes of at least 5 animals). Quantification of Htt-
aggregates in distinct brain regions of 14 wk-old R6/2 mice showed the largest aggregate load 
is present in the hippocampus and striatum, whereas cortex and cerebellum contained 2 to 3-
fold less Htt-aggregates (Figure 27).  
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Figure 27: Quantification of relative Htt-aggregate load in different brain regions of 13 wk-old R6/2 mice (n=5) 
reveals that aggregate deposition is most pronounced in the hippocampus and striatum.  
 
Next, we analyzed Htt-aggregate formation in the HdhQ150 knock-in mouse model which 
was generated by inserting an elongated polyQ stretch of 150 glutamines in the endogenous 
mouse huntingtin gene (Lin et al., 2001). Typical for full-length polyQ-Htt models, in the 
HdhQ150 mice disease-onset and progression is delayed when compared to Htt-fragment 
models such as the R6/2 mice. First phenotypic alterations in HdhQ150 mice are observed 
starting from about one year of age (body weight loss) or from 18 months of age on the 
RotaRod (Woodman et al., 2007). In contrast, we detected Htt-aggregates in HdhQ150 brain 
samples already at 6 months of age, at this age the AGERA signal was 3.4-fold above 
background of wt littermates (Figure 28).  
 
Figure 28: Onset and accumulation of Htt-aggregates during disease progression were confirmed in cortical 
samples from the full-length Htt knock-in model HdhQ150 from 6, 10, 18 and 22 months old HdhQ150 mice (n= 
3-4, *=p<0.05, **= p<0.01, *** = p<0.001) 
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We then found an age- and disease progression-dependent increase in the load of Htt-
aggregates, reaching a 9.0-fold difference at 10 months, 13.9-fold at 18 months and 20.1-fold 
at 22 months of age (all groups n=4 but n=3 for the HdhQ150 mice at 6 months). No 
aggregate signal was detected in 6 months old mice and signal failed to reach significant 
levels before 18 months of age with the filter trap assay (data not shown). Overall, our data 
demonstrate that sizable amounts of Htt-aggregates appeared before the onset of disease 
symptoms in two mouse models of HD. 
 
Age-dependent growth of brain Htt-aggregates  
In our in vitro studies we demonstrated that AGERA is not only an accurate method to 
measure quantitatively the absolute amount of Htt-aggregates, but that this methodology has 
also the potential to reveal qualitative changes in their appearance. Age-dependent growth of 
Htt-deposits in vivo has been observed previously in immunohistochemical studies on brain 
sections isolated from brains of HD patients or of R6/2 mice (DiFiglia et al., 1997; Li et al., 
1999). To confirm this biochemically, we analyzed brain homogenates of 4 and 14 wk-old 
R6/2 mice on a long 1% agarose gel in order to maximize the resolution of distinct Htt-
aggregate species. This procedure established that in young mice Htt-aggregates had faster 
average mobility, since they were detected in the lower half of the agarose gel (Figure 29). In 
contrast, Htt-aggregates from brain samples of 14 wk-old mice scattered over most of the gel. 
This was more evident with a short exposure of the gel to compensate for the larger amount of 
aggregates present at 14 wk of age.  
 
Figure 29: Brain homogenates from 4 or 14 wk-old mice were run on a long 1% agarose gel and immunoblotted 
with the MW8 antibody (left panel). A long and a short exposure of the same blot were done in order to compare 
signals with similar intensity for the two ages. Dotted lines indicate the distribution of the aggregates on the 
agarose gels in the 14 wk-old (left lane) and in the 4 wk-old (right lane) R6/2 brains. Aggregates are significantly 
larger in older mice, also confirmed by determining the relative apparent mobility using densitometric scans of 
the gels (right panel).  
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Histological examinations also indicated that the localization within the cell may have an 
effect on the size of the Htt-deposits (Gutekunst et al., 1999; Stack et al., 2005). In fact, 
neuropil inclusions appeared initially small but then grew faster than those observed in the 
nuclei of affected neurons. To revisit this finding, we isolated cytoplasmic and nuclear 
fractions from brains of 6, 8 and 14 wk-old R6/2 mice. The purity of the two subcellular 
fractions was verified using cytoplasmic and nuclear markers, respectively (Figure 30, lower 
panels). When using AGERA, we indeed observed that the aggregates present in the 
cytoplasmic fraction at 6 and 8 wk of age migrated faster than those detected in the nuclear 
fractions of the same samples. These data demonstrated that cytoplasmic aggregates were 
smaller than nuclear aggregates in brains of 6 or 8 wk-old R6/2 mice.  
 
 
Figure 30: Cytoplasmic (C) and nuclear (N) fractions were isolated from brains of 6, 8 and 14 wk-old R6/2 mice. 
Purity of the fractions was confirmed with a cytoplasmic (α-tubulin) and a nuclear marker (histone) by Western 
blot after SDS PAGE. Samples were resolved by AGERA on a long 1.5% agarose gel and using the MW8 or the 
anti-ubiquitin antibody. A clear increase in the size of cytosolic aggregates occurs between the age of 8 and 14 
wk. Nuclear aggregates are larger than the cytoplasmic aggregates at 6 wk of age but their size does not change 
significantly with disease progression. More aggregates localize into nuclei at 14 wk of age, but ubiquitination is 
more prominent in the cytosolic fractions and is more pronounced for the larger aggregates. 
 
A significant increase in the size of the cytoplasmic aggregates was observed between the age 
of 8 and 14 wk. In contrast to this, the size of nuclear aggregates remained constant with age. 
Moreover, the use of anti-ubiquitin antibodies revealed that in particular the slow-migrating 
aggregates were ubiquitinated. Not surprisingly, modification with ubiquitin was more 
prominent for cytosolic than nuclear aggregates (Figure 30), contradicting earlier histological 
studies (Li et al., 1999). Further studies may help understanding whether location and size of 
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Htt-aggregates might have differential roles in the manifestation of HD as previously 
suggested by others (Yang et al., 2002). 
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4.2.5 DISCUSSION 
The genetic cause for Huntington’s Disease is an aberrant polyQ-expansion in Htt. PolyQ-
length regulates deposition of Htt-fragments into intracellular aggregates (Chen et al., 2002; 
Huang et al., 1998) whose number correlates with disease progression in HD patients and 
animal models (DiFiglia et al., 1997; Gutekunst et al., 1999; Menalled et al., 2003; van Roon-
Mom et al., 2002; Woodman et al., 2007). Precise quantification of the amount of aggregates 
present in biological samples has proven challenging due to analytical limitations such as high 
background in the filter-trap assay or indirect quantitative determination by histochemistry. 
For instance, the filter-trap assay often retains contaminants such as tissue debris, which may 
include soluble Htt-forms and adsorb unselectively antibodies, both reducing the signal 
specificity. AGERA overcomes this and other limitations as it is based on active 
electrophoretic separation of aggregates. Moreover, soluble (monomeric and oligomeric) Htt-
species migrate fast through the agarose gels thereby becoming fully resolved from insoluble 
aggregates. The negligible background signals obtained by AGERA may indeed explain the 
drastic improvement in Htt-aggregate detection sensitivity, also when compared to other 
agarose-gel methods (Kushnirov et al., 2006). This will become critical for a comprehensive 
study of cellular and rodent models of HD. We showed that in cultured striatal neurons 
expressing mHtt-Exon 1, aggregates formed several days before onset of neurite degeneration. 
In vivo, a significant amount of Htt-aggregates was measured in the brains of R6/2 mice at 
two weeks of age, preceding the development of first motor impairments by weeks (Carter et 
al., 1999; Lione et al., 1999; Mangiarini et al., 1996). Aggregates have been previously 
detected in defined areas of the cortex and striatum of R6/2 mice at 3.5 and 4.5 weeks of age, 
respectively (Davies et al., 1997). A more recent study reported the immunohistochemical and 
electronmicroscopical detection of very small Htt aggregates as early as postnatal day 1 and 
15 (Stack et al., 2005). 
We reproduced these findings in a second HD mouse model. In HdhQ150 mice, Htt-
aggregates were detected at 6 months of age, about half a year earlier than the first discernible 
phenotype. Detection of Htt-aggregates in HdhQ150 mice, which express full-length polyQ-
Htt, suggests that AGERA may also be applicable for the analysis of aggregates in human 
tissue.  
In addition to the determination of the total amount of aggregated Htt, we studied by AGERA 
aggregate growth and composition. We showed that disease progression correlated in R6/2 
mice not only with an increase of the amount of Htt-aggregates but also with an increase in 
their size, and this depending on their intracellular localization. Notably, Htt-deposits in the 
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cytosol were smaller than those found in the nucleus in young R6/2 mice but grew 
dramatically between 8 and 14 weeks of age. These data suggest that the microenvironment 
may affect Htt-deposition and hinted that nuclear and cytosolic aggregates may differently 
impact specific cellular functions. Also, the ubiquitination level of Htt-aggregates was more 
prominent in the cytoplasmic than the nuclear fraction. In light of recent findings that 
hindrance of the proteasome clearance pathway by ubiquitinated Htt may induce autophagy 
(Bence et al., 2001; Iwata et al., 2005; Jana et al., 2001), AGERA could become a critical 
method to study ubiquitination or other posttranslational modifications of Htt-aggregates and 
their influence on cytotoxicity or induction of protective mechanisms such as autophagy. 
Determination of changes in aggregate size was particularly important in three aspects of this 
work. We first demonstrated that Congo Red inhibited mainly aggregate growth but less so 
their total amount. Then, we showed that deposit size correlated with disease progression. 
Finally, we illustrated that in this respect nuclear and cytosolic aggregates behaved differently. 
The role of aggregates in HD is still under debate. While some researchers argue that 
aggregates are toxic and lead to neurodegeneration, others have suggested that they are a mere 
byproduct of the pathology. Yet others discuss a neuroprotective role for aggregates as a 
molecular sink for putative soluble toxic Htt forms (Arrasate et al., 2004; Saudou et al., 1998). 
It is to be expected that aggregate localization will influence toxicity to a larger extend than 
aggregate size or composition. Indeed nuclear rather than cytosolic Htt-aggregates led to a 
very quick cell death and this independently of polyQ-length (Saudou et al., 1998, Bates, 
2003; Chen et al., 2001; Chen et al., 2002; Yang et al., 2002). Also, it has been reported that 
the smaller, more aggregation prone fragments of mHtt were found preferentially in the 
nucleus (Lunkes and Mandel, 1998; Wellington et al., 2000a). Interestingly, the study of a 
conditional mouse model of HD demonstrated that development and progression of a HD-like 
pathology was dependent on the continuous expression of the transgene. In fact, switching off 
Htt-expression stopped disease progression, reversed aggregate load and improved motor 
deficits (Martin-Aparicio et al., 2001; Yamamoto et al., 2000). Most pre-clinical trials failed 
to show a decrease of aggregate formation in the brain of HD mouse models, although 
occasionally motor behavior or striatal volume loss improved (Ferrante et al., 2004; Gardian 
et al., 2005; Smith et al., 2006). However, assessment of aggregates in these studies was 
mostly limited to immunohistochemical analysis. The use of AGERA has improved 
sensitivity and reproducibility of our analysis and has allowed for active resolution of Htt-
aggregates based on size. In light of this, although our study does not solve the problem of the 
role of aggregates in the pathology of HD, AGERA enables a sensitive and quantitative 
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assessment of aggregate load and therefore is expected to enable their detailed analysis and 
thus significantly improve the power of future pre-clinical HD drug trials. 
As protein misfolding and deposition are hallmarks of not only HD but also most other 
neurodegenerative diseases, AGERA may find application for the study of the pathogenic 
processes in other human brain disorders and may allow for comparative studies of the many 
neurodegeneration models developed over the recent years. Indeed, agarose gel 
electrophoresis has been recently used to study prion polymerization in yeast (Kushnirov et al., 
2006), to analyze fibril generated in vitro from synthetic β-amyloid peptide (Bagriantsev et al., 
2006) and readily detects aggregation of other pathogenic polyQ-containing proteins (A. 
Weiss, unpublished results). The development and optimization of AGERA aimed at the 
specific analysis of protein aggregates in cellular and tissue samples. While AGERA is in 
principle similar to the agarose-based method described independently by Kushnirov and 
colleagues, in order to generate reliable data enabling comparative studies using large sample 
sizes and granting reproducibility among independent experiments it was critical to keep all 
AGERA parameters constant. It will be interesting to see if AGERA can be used to trace 
changes within disease specific aggregate pools, specifically for visualization of subtle 
differences caused by experimental drugs.  
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4.3.1 SUMMARY 
The quantification of cellular proteins is essential for the study of many different biological 
processes. This study describes an assay for the detection of intracellular mutant huntingtin, 
the causative agent of Huntington’s Disease, with a method that may be generally applicable 
to other cellular proteins. A small recombinant protein tag was designed that is recognized by 
a pair of readily available, high affinity monoclonal antibodies. This tag was then added to an 
inducible fragment of the mutant huntingtin protein by genetic engineering. First we 
demonstrated that it is possible to use time resolved Förster resonance energy transfer (time 
resolved FRET) to detect the cellular levels of this protein by a simple lysis and detection 
procedure. This assay was then adapted into a homogeneous, miniaturized format suitable for 
screening in 1536 well plates. The use of time resolved FRET also allows the assay to be 
multiplexed with a standard readout of cell toxicity thus detecting conditions causing 
reduction of protein levels simply due to cell toxicity. Screening results demonstrated that the 
assay is able to identify compounds that modulate the levels of huntingtin protein both 
positively and negatively. 
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4.3.2 INTRODUCTION 
Huntington’s Disease (HD) is a fatal, autosomal-dominant neurological disorder. The disease 
is characterized by involuntary movements, severe emotional disturbance and cognitive 
decline caused by a significant degeneration of brain matter (Bates et al., 2002). In 1993, the 
gene IT15, later called huntingtin (Htt), was cloned and found to contain a CAG repeat 
encoding for polyglutamine (polyQ) in exon 1 which is expanded in patients (Group, 1993a; 
Gusella et al., 1983). A number of possible effects on cell physiology by this polyQ region 
have been suggested including the generation of cytotoxic proteolytic fragments and 
aggregates, transcriptional dysfunctions and several other effects. Currently, there are no 
approved treatments for HD (Bates, 2003; Bates and Hockly, 2003; Landles and Bates, 2004; 
Young, 2003). 
Even though the mechanism of polyQ-Htt toxicity is unknown, it has been shown in mouse 
models that down-regulation of polyQ-Htt expression either by RNA interference (DiFiglia et 
al., 2007; Machida et al., 2006; Rodriguez-Lebron et al., 2005; Wang et al., 2005) or by 
conditional expression of a polyQ-Htt-fragment (Yamamoto et al., 2000) will improve HD-
like symptoms significantly. Critically, polyQ-Htt and wild-type Htt are distinct in terms of 
posttranslational modifications (e.g. phosporylation (Warby et al., 2005)), proteolytic 
cleavages (Graham et al., 2006; Wellington et al., 2002), cellular localization (Davies et al., 
1997) and degradation (ubiquitin/proteasome or autophagy pathway (Ravikumar et al., 2002)). 
As polyQ-Htt is the sole cause for HD and as the cell metabolizes polyQ-Htt and wild-type 
Htt differently, we established an assay capable of detecting the intracellular levels of wild-
type and polyQ-Htt. In order to develop this assay, neuronal cell lines with inducible copies of 
either the wild-type or polyQ-Htt, tagged with small peptide sequences were created and a 
method was developed to detect compounds which selectively promote the degradation of 
polyQ-Htt. 
In general, most methods to monitor cellular protein levels require separation and detection 
steps e.g. Western blotting or HPLC-MS. Such methods are not suitable as assays to test 
multiple conditions, i.e. high throughput screening of chemicals or siRNAs as high throughput 
screening applications require homogeneous assays that are robust enough to allow assay 
automation. To circumvent these problems, we developed an alternative method using time 
resolved Förster resonance energy transfer (time resolved FRET), a technology that has been 
available for monitoring biomolecular interactions since the early 1990’s (Mathis, 1993). 
There are many different applications of this technology utilizing several aspects of the 
fluorescence characteristics of lanthanide ions. The large Förster’s distance of the rare earth 
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ions is up to 9 nm which is much larger than for many fluorescent compounds which have 
Förster’s distances of between 4-6 nm. The effect of this larger distance is that it is possible to 
transfer absorbed energy over much longer distances than it is possible for many FRET pairs. 
This then makes it possible to use rare earth chelates as generic immunodetection reagents 
(Bazin et al., 2001). The second advantage of rare earth FRET pairs is that the time it takes for 
the fluorescence to decay is greatly delayed thus allowing time resolved fluorescence. The 
effect of this is to reduce the influence of background fluorescence from small molecules 
being tested. The third advantage is the ability to monitor ratiometric readouts allowing the 
correction for liquid dispensing errors, thus helping to reduce assay variability and improve 
data quality (Imbert et al., 2007). 
Because of these advantages, time resolved FRET has been used in the past to monitor a 
number of different biological analytes such as small molecules (e.g. cAMP (Gabriel et al., 
2003)), small secreted cytokines (e.g. IL-8 (Achard et al., 2003)) as well as the levels of 
phosphorylated proteins in in vitro assays (Riddle et al., 2006). There have also been reports 
of using time resolved FRET to monitor the levels of phosphorylated proteins in cell lysates 
using cell lines over-expressing protein substrates of interest. In this report we extent these 
observations by designing a small peptide tag that gives an optimal time resolved FRET signal 
and allows the detection of polyQ-Htt, an intracellular protein expressed at endogenous levels. 
As polyQ-Htt detection in this assay is based on an artificial tag, this method should be 
generally applicable for the detection of other proteins. Importantly, the required antibody 
pairs for tag detection are commercially available (see Material and Methods) making the 
herein described method a readily applicable generic detection method for other laboratories. 
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4.3.3 MATERIALS AND METHODS 
Peptides and Antibodies 
Peptides carrying epitopes against 25H10, 32A7 or ß1 antibodies which are separated by 
different linker sequences were custom produced by MIT biopolymers laboratory (MIT, 
Cambridge, MA). Amyloid ß40 peptide was purchased from Bachem (Bubendorf, 
Switzerland). 
25H10 antibody specific against GGVV-epitope, 32A7 antibody specific against VVIA and 
ß1 antibody directed against EFRH are described elsewhere (Paganetti et al., 1996; Weihofen 
et al., 2003). Commercially available unlabeled antibodies equivalent to these antibodies can 
be obtained through several vendors such as Cell Sciences (MA, USA), The Genetics 
Company (Switzerland) or Immuno-Biological Laboratories (MN, USA). Labeled antibodies 
ready for time-resolved Förster Resonance Energy transfer can be obtained through Cisbio 
Bioassays (France). 2B7 antibody was custom designed against the first 17 amino acids of Htt 
protein (GENOVAC, Freiburg, Germany). Custom europium cryptate and D2-fluorophore 
labeling were performed by Cisbio Bioassays (France). Depending on the batch used, 
antibodies were crosslinked to 5 to 7 mol europium cryptate or D2-fluorophore per mol 
antibody. 
 
Generation of Neuronal Cell Lines 
Neuronal HN10 cells (Lee et al., 1990) were used to create inducible clones with expression 
of Htt573-Q25 and/or Htt573-Q72. In short, cells were transfected with the rheoswitch 
receptor plasmid (New England Biolabs) and cultured under selection of 1 mg/ml G418 
(Invitrogen). Clones were screened for cell morphology, transfected with inducible luciferase 
reporter construct and induced for 2 days. Clone with best induction ratio were selected and 
used for subsequent transfection with Htt573-Q25 or Htt573-Q72 inducible plasmid. After 
selection with 1 mg/ml G418 and 1 mg/ml Hygromycin (Invitrogen), inducible expression of 
Htt fragments in the clonal lines were monitored with herein described time resolved FRET 
detection method and clones with no basal expression and highest inducible expression were 
chosen for use in the assay format. 
 
Detection of Peptides by time resolved FRET 
Peptides were prediluted in DMSO to 800 µg/ml. DMSO solutions were further diluted in 1 to 
5 RIPA buffer to 3 ng/ml final concentration. 3 ng/ml amyloid ß40 peptide was used as 
control. 10 µl peptide solution per low-volume 96-well were mixed with 5 µl of antibody 
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solution (ß1–D2 20 ng/well, 25H10-K 2 ng/well in 50 mM NaH2PO4, 400 mM NaF, 0.1% 
BSA, 0.05% tween) and incubated at 4 °C overnight. 620 and 665 nm signals were measured 
with a RUBYstar (BMG Labtech) reader. 
 
Adaptation to 96 Well Format 
20.000 cells/well were seeded in 100 µl normal grow medium (DMEM (Gibco), 10% FCS, 
penicillin and streptomycin). After 2 h medium was removed and 200 µl inducing medium 
(normal growth medium plus inducer) was added to start expression of Htt fragments. After 3 
days, medium was removed and 30 µl/well readout buffer (20 µl of different lysis buffers and 
10 µl of ß1-D2 and 25H10-K or 32A7-K in 50 mM NaH2PO4, 400 mM NaF, 0.1% BSA, 
0.05% tween) was added. After incubating 30 min at room temperature, lysates were 
transferred to low volume black bottom 96 well plate. After 3 h at 4°C 620 and 665 nm 
signals were measured with a RUBYstar (BMG Labtech) reader. 
 
1536 Well HTS Miniaturization and Compound Screen  
A Htt573-Q72 expressing HN10 cell line was incubated for 72 h at 37°C, 5% CO2 with 
inducing medium to facilitate expression of polyQ-Htt construct. Then 3 µl of a 2000 cells/µl 
cell suspension were added per well in a 1536-microtiterplate (Greiner) and incubated 
overnight -/+ compound treatment. 5 µl of sample buffer solution (3 µl lysis buffer [1x PBS + 
1% Triton X-100, complete protease inhibitors] + 2 µl antibody buffer [50 mM NaH2PO4, 400 
mM NaF, 0.1% BSA, 0.05% tween, 60 pg/well europium labeled antibody, 800 pg/well D2-
labeled antibody]) was added and incubated for 30 min at room temperature. Plates were 
incubated at room temperature as indicated. Measurements were performed with a View Lux 
machine with the following settings: Label 1 time resolved FRET_Eu-K_(E:800K, Xsec, BF4, 
GN:high,SP:slow), Label 2 time resolved FRET_XL665_(E:800K, Xsec, BF4, 
GN:high,SP:slow). 
 
Data Analysis 
Time resolved FRET measurement results in two different signals. The 620 nm signal from 
the europium cryptate labeled antibody can be used as an internal reference for possible 
interfering artifacts of the assay such as signal quenching or absorption by compounds, 
sample turbidity as well as differences in excitation energy or sample volume. The 665 nm 
signal results from D2 labeled antibody which is excited by time resolved energy transfer 
from the europium cryptate. The calculated 665/620 nm ratio therefore is an artifact corrected 
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specific signal of the two antibodies bound to their antigen and hence a reflection of the 
amount of antigen present in the sample. For 96 well data time resolved FRET signals are 
given as the ratio between those two wavelengths. 
For 1536 microtiter well optimization data, time resolved signals are presented as ∆F values, a 
format more suitable to take day-to-day assay variations into account as it is a background 
corrected value: 
∆F = (Ratio665/620induced - Ratio665/620non-induced ) / Ratio665/620non-induced * 100 
Analysis of high throughput screening data was conducted using an in house data analysis 
software. This software is able to normalize activity to percent remaining activity with the use 
of high and low control samples present on a plate and to correct plate effects using a local 
regression algorithm that corrects for local plate effects (Gubler, 2006). Z-factor was 
calculated according to (Zhang et al., 1999). 
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4.3.4 RESULTS 
Technology Development 
Time resolved FRET detection of amyloid ß peptide in fluid biological milieu has been 
previously described (Clarke and Shearman, 2000) and is currently commercially available. 
The amyloid sandwich assay takes advantage of high-affinity antibodies directed against two 
well characterized epitopes in the amyloid ß peptide. We designed a library of small peptides 
which carry these epitopes (Figure 31A). Our goal was to use this peptide sequence as a tag 
for recombinant proteins, making them suitable for time resolved FRET detection. Since the 
efficiency of the FRET energy transfer can be influenced by various parameters (Clegg, 1996; 
Förster, 1948) we tested different peptides with changing linker length and amino acid 
composition to determine the most suitable peptide sequence. Time resolved FRET analysis 
of purified peptides showed that linker length and sequence of the linker can indeed influence 
signal intensity significantly (Figure 31B). For example, peptides with very short linker length 
(peptides H2 and H3) resulted in low signals probably due to steric hindrance of the two 
antibodies. Peptide I6 in which the neo-epitope GGVV specific for 25H10 antibody was 
exchanged for VVIA (specific for 32A7 antibody) failed to result in a signal when using the 
25H10 europium labeled antibody (25H10-K), verifying the specifity of the signal. For further 
experiments we designed two Htt-protein-fragments carrying either the exact H1 peptide 
sequence as a tag (polyQ-Htt/Htt573-Q72) or an alternative sequence in which the neo-
epitope GGVV was exchanged for VVIA (wild-type Htt/Htt573-Q25) (Figure 31C). We 
created clonal neuronal HN10 cell lines (Lee et al., 1990) with inducible expression of either 
polyQ-Htt, wild-type Htt or polyQ-Htt and wild-type Htt together. These cell lines were 
subsequently used to establish a cellular high-throughput time resolved FRET assay for 
detection of cellular protein levels (Figure 31D).  
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Figure 31: Detection tag and linker optimization, protein constructs and assay principle. A: Optimization 
of linkers. Peptide sequences analyzed with 25H10 and ß1 antibodies are shown with epitope sequences for 
antibodies in bold letters. B: Time Resolved FRET analysis of the peptides indicated that peptide H1 is best 
recognized by the antibody pair. H1 peptide sequence was subsequently chosen as an artifical tag (3 ng 
peptide/well loaded, duplicates for each peptide shown). C: Final constructs that are expressed in the clonal 
neuronal cell lines and detection sites of antibodies used. 25H10, 32A7 and ß1 antibodies detect epitopes at the 
carboxyterminal tag of the constructs, 2B7 antibody detects an endogenous Htt epitope at the aminoterminus. 
Neuronal HN10 clonal cell lines with inducible expression of tagged Htt constructs were created for the assay. 
D: Concept behind the assay. 
 
Protein Detection and Signal Specificity  
The neuronal clonal cell lines created expressed the tagged polyQ-Htt and wild-type Htt at 
levels corresponding to that of endogenously expressed Htt upon full induction with no 
detectable basal expression as demonstrated by western blot analysis (Figure 32A,B). 
Expression levels of the constructs after induction were stable over time (Figure 32B). 
Experiments using a 96-well format showed that highly specific time resolved FRET 
detection of either the wild-type- or polyQ-Htt-protein in a cellular context was feasible when 
using the antibody pairs 25H10-K + ß1-D2 or 32A7-K + ß1-D2 which detected specifically 
their corresponding tags. In addition, using the 2B7-K antibody specific for an aminoterminal 
endogenous Htt epitope in combination with the ß1-D2 antibody specific for an epitope at the 
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carboxy-terminal tag, allowed for selective detection of non-cleaved, intact Htt-protein 
(Figure 32C) in the cell lines expressing either wild-type or polyQ-Htt. 
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Figure 32: Detection of induced constructs in neuronal cell lines with time resolved FRET. A: Western blot 
for wild-type (Htt573-Q25) and polyQ-Htt (Htt573-Q72) shows expression levels near endogenous levels of full 
length Htt as well as absence of basal expression without addition of inducer. B: Western blot of cell lysates 
from clone with inducible co-expression of the wild-type and polyQ-Htt constructs. Expression levels are stable 
over passages and time. C: Detection of constructs in 96-well format with time resolved FRET method proves 
sensitivity and specificity of the assay. After induction of expression, wild-type and polyQ-Htt are specifically 
detected only by the antibody pairs corresponding to the tags. 
 
In order to determine the maximal expression levels of polyQ-Htt-protein in the HN10 
Htt573-Q72 cells, we first calibrated our assay using increasing H1 peptide concentrations 
diluted into PBS or cell lysates from noninduced cells (Figure 33). After determining the 
linear range and intensity of the time-resolved FRET signal for a given H1 peptide amount in 
cell lysates, we were able to calculate an expression level of polyQ-Htt-protein (which carries 
the H1 peptide as a tag) corresponding to 17 ng Htt per mg total cellular protein. This 
intracellular concentration of polyQ-Htt was significantly higher than the detection limit of 
the assays calculated as 3-fold standard deviation over the background signal (3.6 ng polyQ-
Htt per 1 mg total cellular protein). 
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Figure 33: Detection sensitivity of H1 peptide for 25H10-K + ß1-D2 antibody combination. Increasing 
amounts of H1 spiked into noninduced cell lysates of Htt573-Q72 clone and time resolved FRET detection with 
25H10-K + ß1-D2. All data points n=3, error bars =stdev. 
 
Assay Miniaturization 
Next, we adapted the assay to a 1536 microwell format. To this end, we selected the Htt573-
Q72 expressing HN10 cell line and used the 2B7-K plus ß1-D2 antibody combination in order 
to quantify uncleaved polyQ-Htt-protein. One of the advantages of using the ratiometric 
readout in the time resolved FRET method is that adaptation to a miniaturized assay format is 
readily facilitated because the assay signal is not dependent on the path length of the detection 
system or the absolute number of particles being detected. In addition ratiometric readout are 
also more robust to errors in liquid handling again facilitating assay miniaturization (Imbert et 
al., 2007). As liquid transfer is difficult and time consuming in a 1536 well plate format it was 
especially important that our detection was based on a totally homogeneous assay format 
whereby no liquid transfer or removing steps were necessary.  
After miniaturizing the format to cells grown directly in a 1536 microwell plate, the assay 
protocol was optimized for lysis buffer (Figure 34A) and signal development over time 
(Figure 34B). Even though induced-to-non-induced signal ratio improved as a function of 
incubation time, the Z’ value already reached a maximum of 0.86 after shorter incubation 
periods (Figure 34B). We proceeded to optimize the detection conditions by determining the 
minimal inducer concentration for maximal induction of expression. Induction of polyQ-Htt 
expression showed good response to changing inducer concentrations, with an EC50 
corresponding to ~250 nM (Figure 34C) and a Z’ value of 0.87 between signals at 400 nM 
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and 200 nM inducer, showing the reliability of the assay for a partial (~50%) reduction in 
polyQ-Htt. 
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Figure 34: Optimization of Htt construct detection in neuronal cell line with time resolved FRET. A: 
Influence of lysis buffer on assay performance for the detection of the Htt573-Q72 construct with the 2B7-ß1 
antibody combination (measurement after 50 min, n=6). B: Time dependency of signal showed increase in 
induced-to-non-induced ratio but relative stability of Z’ over time (Htt573-Q72 construct, n=6). C: Expression 
levels of Htt573-Q72 in response to increasing inducer concentration (n=6, IC50 ~250 nM). 
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Figure 35 presents some of the additional assay validation steps taken to characterize the 1536 
well assay. First, the DMSO tolerance of the assay was tested to ensure that DMSO, which is 
used as the compound salvation agent, did not affect the assay signal by altering cell growth 
(Figure 35A). DMSO was well tolerated up to a concentration of 1%. The effect of cell 
density on the assay robustness was determined by assessing the Z’ value (using induced and 
non-induced cells as high and low controls) at different cell densities with or without 
multiplexing the detection of Htt levels with a measure of cell viability (the reduction of 
resazurin as a measure of mitochondrial activity, Figure 35B) (O'Brien et al., 2000). The Z’ 
values remained constant over a range between 6000 and 8000 cells/well and multiplexing 
with the cytotoxicity assay had no influence on the robustness of the assay. Since unbound 
europium cryptate labeled antibody can contribute to non-specific background signal in time 
resolved FRET assays, it was important to select the most appropriate dilutions of the two 
monoclonal antibodies used in the assay. An example of optimization of antibody 
concentrations is shown in Figure 35C. 
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Figure 35: Optimization of assay conditions for high-throughput-screen. A: Shows the DMSO tolerance of 
the assay. B: Z’ calculation at different cell densities, in the presence and absence of resazurin. C: Antibody 
titration to optimize the relative antibody concentrations for construct detection after induction. 
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High Throughput Screening 
Following miniaturization, the assay was first applied for screening a small library composed 
of ~10000 compounds commonly used in house for validating the assay performance before 
commencing screening the full deck library. This allowed to monitor the assay performance 
under real HTS screening conditions. Importantly, this also resulted in the identification of a 
small number of primary hits, which can be used to further characterize the secondary assays 
destined for triaging the total number of hits identified by the full primary screen. 
Analysis of the prescreen values demonstrated excellent performance with Z’ values 
averaging at ~0.6 among multiple plates. Close inspection of the primary results however did 
show that there was a small, but significant “edge effect” in all plates tested in the prescreen. 
This edge effect was more evident when viewing the correction pattern of the plates analyzed 
(data not shown) or when the results of this focused screen were arranged by well number 
(Figure 36A). This view showed a regular “saw tooth” pattern due to the plate edge effects. 
However, this effect was only minor and did not affect much the statistics of the assay 
performance, as shown in Figure 36B with the primary data presented in a Gaussian 
distribution.  
A B
 
Figure 36: Screening performance. A: Scatter plot of the screening data with the x-axis being the well number 
for each of the samples. The slight “saw-tooth” pattern of the results show how even after “correction” of the 
results a slight effect of the plate effect is apparent.  However, the actual magnitude of this plate effect is actually 
less than 20% activity. B: Frequency distribution of the results obtained for the samples tested (colored green) 
and the positive controls (noninduced cells, colored red). 
 
Comparison of Results Using Resazurin 
In addition to testing assay performance with the standard single readout format (Figure 37A) 
a smaller subset of the preplated compounds were also multiplexed for cell viability, which 
was monitored before cell lysis, and protein detection by time resolved FRET (Figure 37B). 
As shown in Figure 37C, both assay formats performed equally well. If anything, the data 
generated by the multiplexed readout appeared less scattering. Comparison of the compound 
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activity in the two assay formats showed that 90% of the compounds identified as hits in the 
single readout format were also identified in the dual readout format with a general hit rate of 
~0.4% (activity cut-off: 3-fold standard deviation over the mean signal), confirming high 
reproducibility and reliability of the time resolved FRET readout. 
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Figure 37: Comparison of screening results in the presence or absence of resazurin. A: Standard single 
readout format. B: Subset of plates tested with a multiplexed readout. Plates were tested for cell viability with 
resazurin and polyQ-Htt levels with time resolved FRET C: Comparison of single readout and multiplex readout 
hits. Both assay formats resulted in similar performance with 90% of the compounds identified as hits in the 
single readout format also being found in the multiplex readout format with a general hitrate of ~0.4%.  
 
Both assay formats were able to identify compounds that increased the levels of polyQ-Htt 
protein present in the cells. Though not of primary focus in our screen, it should be noted that 
since we measured the levels of intact polyQ-Htt and since proteolytic cleavage of polyQ-Htt 
influences its toxicity (Gafni et al., 2004; Wellington et al., 2002), these compounds could 
potentially be of interest as Htt cleavage inhibitors or of general interest to characterize our 
cellular model systems. 
 
 78 
Characterization of Active Compounds 
The Novartis compound archive contains one of the largest collection of purified natural 
products. Screening of these compounds has the advantage that many of the compounds have 
previously reported activity and their mechanism of action is known, thus suggesting possible 
targets involved in the cellular regulation of polyQ-Htt expression. 
As noted previously, 12 compounds out of the ~10000 compounds in the prescreen were 
found to increase polyQ-Htt protein in both assays. Even though Htt cleavage inhibitors of 
potential therapeutic use could belong to this compound group, the majority of compounds 
increasing polyQ-Htt levels were expected to act via unspecific pathways. Indeed, 8 of these 
compounds were chlamydocin or trichostatin A analogues, common HDAC inhibitors that 
lead to a general increase of gene expression (Table 1, #1,2) (De Schepper et al., 2003; 
Nishino et al., 2004; Yoshida et al., 1995).  
More interesting were a number of compounds effectively lowering polyQ-Htt expression 
although these compounds may work by some non-specific effect or by perturbing cell 
viability. For example cycloheximide, borrelidin and anisomycin (Table 1, #4-6) lowered the 
levels of polyQ-Htt but did not influence cell viability over the incubation time of this assay. 
All three compounds are known to be general inhibitors of protein synthesis (Baliga et al., 
1969; Grollman, 1967; Nass, 1970). Additionally, a number of staurosporine analogues 
(unselective protein kinase inhibitors; Table 1, #3), as well as BAY 61-3606 (a specific syk 
kinase inhibitor; Table 1, #7 (Yamamoto et al., 2003)) are known to interfere with various 
cellular pathways.  
Even though many compound hits in our assay will act via unspecific pathways such as those 
described in the previous paragraph, the dynamic response of the assay to compounds with 
known mechanism of action was very encouraging. Further validation of the compounds 
lowering neuronal expressed polyQ-Htt by unknown biological mechanisms of action is in 
process as well as a full screen of the Novartis compound library.  
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# Compound Structure Biology Activity in assay in %
1 Trichostatin A analogue HDAC Inhibitor 68
2 Trichostatin A analogue HDAC Inhibitor 67
3 Staurosporine Proteinkinase Inhibitor -84
4 Anisomycin Proteinsynthesis Inhibitor -79
5 Cycloheximide Proteinsynthesis Inhibitor -74
6 Borrelidin Proteinsynthesis Inhibitor -73
7 BAY 61-3606 SYK kinase Inhibitor -27
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Table 1: Selection of compounds with known biological mechanism of action and their activity in the assay. 
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4.3.5 DISCUSSION 
This report describes the design and implementation of an assay that allows the quantification 
of proteins, even those expressed at endogenous levels. The assay format is homogenous and 
robust enough to allow miniaturization for high throughput screening. The assay format has 
been used to identify compounds that modulate the intracellular levels of the polyQ-Htt 
protein fragment and possibly represents the first assay that is capable of measuring the steady 
state levels of this protein. 
There are still a number of caveats with this assay format though. First, it appears that the cell 
lysis conditions need to be optimized for each set of protein and antibody detection reagents 
(unpublished results). Second, it appears that the assay is only detecting proteins that are 
solubilized during cell lysis which might mean that this format would not be suitable for 
monitoring the levels of proteins involved in large macromolecular complexes that are not 
readily solubilized (e.g. proteins associated to the cell cytoskeleton or to the nuclear structure). 
Third, because a recombinant peptide tag has been added to facilitate detection there are a 
number of possible caveats including that the endogenous untagged protein levels may differ 
from the detected signal. Such a caveat depends on the fate of the detection tag because of 
potential proteolysis. The peptide tag may also have an effect on the physiology of the protein 
being studied. Fourth, while it is possible to multiplex this assay format with an assay to 
monitor cell viability, the current assay setup uses a measure of mitochondrial redox potential 
which may not be sensitive enough to detect changes in cell physiology that may alter relative 
protein levels. 
One advantage of this tagging approach is that it allows not only the levels of protein 
expression to be monitored but readily allows detection of the protein for application to 
intracellular imaging assays. This would then make it possible to not only follow the levels of 
protein during a change in conditions but also the protein location within the cell. For Htt this 
is of importance as it has been reported that intracellular localization of Htt influences its 
toxicity (Bates, 2003; Chen et al., 2001; Chen et al., 2002; Yang et al., 2002) and may also 
have a bearing on the apparent protein levels (Gutekunst et al., 1999; Stack et al., 2005). 
While the detection method described in this report has been combined with a readout of cell 
viability, this readout has a tendency to underestimate the potential toxicity of compounds. 
However it is still possible that this assay format could be multiplexed with additional 
readouts such as ATP levels or even other reporter gene assays. 
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Finally, it should be evident that the basic strategy used to detect proteins can be extended to 
assays using antibodies to non-recombinant epitopes allowing endogenous and untagged 
protein to be detected and quantified. 
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4.4.1 SUMMARY 
The genetic mutation causing Huntington's Disease (HD) is a polyglutamine expansion in the 
huntingtin protein. Expansions beyond 39 glutamines become pathogenic and appear to affect 
protein folding and successive formation of toxic intracellular fragments and aggregates. 
Innovative disease-modifying therapeutics for HD may target folding, proteolytic cleavage or 
degradation of mutant huntingtin. Despite the clear causative role of mutant huntingtin, 
assessment of huntingtin expression during disease progression or in presymptomatic HD is 
sparse. We established a highly sensitive detection assay, which allows for single-step 
quantification of soluble mutant huntingtin in biological samples. We found that mutant 
huntingtin levels decrease as a function of disease progression and inversely correlate with the 
amount of aggregates present in brains of HD mice. Specific determination of mutant 
huntingtin was established in blood-derived fractions and brain extracts of HD patients. This 
allows assessing the relevance of mutant huntingtin levels as a disease and/or 
pharmacodynamic biomarker in HD. 
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4.4.2 INTRODUCTION 
Huntington’s Disease (HD) is the most common inherited neurodegenerative disorder with a 
prevalence of 5 to 8 cases per 100’000. Its main clinical manifestations include motoric 
dysfunction, psychiatric disturbances and dementia. Numerous symptomatic treatments have 
been tried for HD without any substantial success (Bonelli and Wenning, 2006) and no 
approved treatments for HD exist (Bates, 2003; Bates and Hockly, 2003; Landles and Bates, 
2004; Young, 2003). HD is the founding member of the polyglutamine (polyQ) disease family 
composed of nine autosomal-dominant inherited disorders whose common characteristic is a 
polyQ-repeat expansion in different ubiquitously expressed proteins (Everett and Wood, 
2004; Ross, 2002). The expanded polyQ repeat in the huntingtin gene (Htt) lies in exon 1 and 
leads to the expression of mutant Htt protein (Group, 1993a; Gusella et al., 1983). The polyQ-
repeat expansion may promote a conversion from a native random-coiled to a cylindrical, 
parallel beta-sheet conformation tethered by hydrogen bonds between the polyglutamine 
strands (Perutz et al., 1994; Perutz et al., 2002b). Similar to other neurodegenerative diseases 
characterized by protein misfolding like Alzheimer’s Disease, the proteins with helical beta-
sheet conformation are prone to form non-soluble protein aggregates (Balbirnie et al., 2001; 
Benzinger et al., 2000; Perutz et al., 2002b).  
HD-like symptoms are reversed when expression of mutant Htt is down-regulated in the brain 
of HD mouse models by RNA interference (DiFiglia et al., 2007; Machida et al., 2006), 
(Rodriguez-Lebron et al., 2005; Wang et al., 2005) or by tetracyclin-regulated conditional 
expression (Yamamoto et al., 2000). Interestingly, mutant and wild-type-Htt are differently 
metabolized by the cell and display a different pattern of posttranslational modifications 
(phosphorylation (Warby et al., 2005)), proteolytic cleavage (Gafni et al., 2004; Graham et al., 
2006; Wellington et al., 2002), cellular localization (Davies et al., 1997; van Roon-Mom et al., 
2002) and degradation (Ravikumar et al., 2002). These findings prompted discovery work for 
HD therapeutics aimed at influencing the misfolding or the clearance of mutant Htt e.g. 
through upregulation of the chaperone system or induction of the autophagy degradation 
pathway (King et al., 2008; Perrin et al., 2007; Yamamoto et al., 2006; Zourlidou et al., 2007). 
Such approaches may find application for other neurodegenerative diseases caused by protein 
misfolding. 
Currently, there is no bioassay available to assess the effect of such therapies on mutant Htt 
levels in clinical trials. We recently described a new homogenous time resolved Förster 
resonance energy transfer method for Htt detection suitable for high-throughput screening in a 
neuronal cell line (Weiss et al. submitted). Here, we show that this method can be modified to 
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quantify endogenous, full-length soluble mutant Htt in cellular, animal and human samples. 
This will enable researchers to address the relevance of soluble mutant Htt as a marker for 
disease progression or to monitor the efficacy of drug treatments in preclinical and clinical 
trials. As the design of the method is highly flexible, it is in principle applicable for 
investigations of other diseases, especially other members of the polyQ-family. 
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4.4.3 MATERIALS AND METHODS 
Antibodies 
25H10, 32A7 and 2B7 antibodies have been described previously (Paganetti et al., 1996; 
Weihofen et al., 2003), (Weiss at al, submitted). MW1 antibody specific against the 
polyglutamine stretch of Htt and developed by Dr. Paul Patterson were obtained from the 
Developmental Studies Hybridoma Bank developed under the auspices of the NICHD and 
maintained by The University of Iowa, Department of Biological Sciences, Iowa City, IA 
52242. Custom europium cryptate and D2-fluorophore labeling of the antibodies were 
performed by CisBio (Bagnols/Ceze, France). Depending on the batch used, antibodies were 
cross-linked to 5 to 7 mol europium cryptate or D2-fluorophore per mol antibody. 
 
Cellular Models 
Inducible, neuronal HN10 cells (Lee et al., 1990) were described elsewhere (Weiss et al., 
2008), (Weiss et al. submitted). The knock-in embryonic stem cells (ES cells) were generated 
as described in (Wheeler et al., 1999; White et al., 1997). The neomycin selection cassette was 
removed by a second electroporation with a plasmid expressing cre recombinase. Embryonic 
stem cell-derived neurons (ES neurons) were generated using the differentiation protocol as 
published by (Bibel et al., 2007; Bibel et al., 2004). In brief, ES cells were cultivated on 
mitomycine-inactivated mouse embryonic fibroblasts for at least two passages after thawing 
in ES medium containing 15% foetal calf serum (FCS) and 1000 U/ml LIF (leukemia 
inducing factor). Subsequently, they were cultured without fibroblast feeder cells for two 
more passages. Embryoid bodies (EBs) were formed on bacterial dishes in EB medium 
containing 10% FCS but no LIF and incubated for 8 days with the addition of retinoic acid on 
the last four days. EBs were dissociated by trypsinisation and plated on poly-l-lysine and 
laminin coated plates in N2 medium and changed to neuronal differentiation medium as 
described by (Brewer and Cotman, 1989) two days after dissociation. 
 
Animal Models.  
Heterozygous transgenic R6/2 males of CBAxC57BL/6 strain were obtained from G. Bates 
laboratory (Mangiarini et al., 1996) and bred with CBAxC57BL/6 F1 females. The offspring 
were genotyped by PCR assay of DNA obtained from tail tissue. The animals were housed in 
a temperature-controlled room that was maintained on a 12 hr light/dark cycle. Food and 
water were available ad libitum. All experiments were carried out in accordance with 
authorization guidelines for the care and use of laboratory animals. For time resolved FRET 
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assay detection of huntingtin, 2-3 months old animals were anesthetized with 3-5% isofluran 
followed by an intraperitoneal dose of 100mg/kg Ketamin and 10mg/kg xylazine. After CSF 
and blood collection, animals were given a sodium pentobarbital overdose (150 mg/kg). 
Muscle (gastrocnemius) and brain were immediately further collected for FRET analysis.  
 
Aggregate analysis by AGERA 
AGERA analysis was performed as described (Weiss et al., 2008). In short, R6/2 brains were 
homogenized in 10 volumes (w/v) PBS + 0,4% TritonX100 and Complete Protease Inhibitor 
(Roche Diagnostics). Brain samples corresponding to 0.15 mg of total protein were loaded per 
AGERA lane. For separation of brain homogenates into soluble and non-soluble fractions, 
homogenates were centrifuged at 124 000 g for 1 h, supernatant was aliquoted (soluble 
fraction) and pellet was resuspended in equal to starting volume PBS + 0,4% TritonX100 
(non-soluble fraction). 
 
Human samples  
HD patient identificication was based on the presence of movement disorders, a positive 
family history and known CAG repeat expansion. Patients were categorized by using the total 
functional capacity (TFC) score assessed by experienced clinical raters. Control subjects 
showed no history of neurological or psychiatric symptoms. Consent of patients was obtained 
according to the Declaration of Helsinski (Br Med J 1991; 302: 1194). Blood samples were 
taken in EDTA-Vacutainer tubes (BD, Oxford) and fractionated by density gradient 
centrifugation using a standard technique to obtain red blood cell and buffy coat (> 90% 
lymphocytes) fractions. 
 
Time resolved-FRET: Cellular models 
Detection of polyQ huntingtin in cell lysates was performed as described (Weiss et al. 
submitted). 
 
Time resolved-FRET: BioAssay 
Brain and muscle tissue were homogenized in 10x volume sample buffer (PBS + 1% Triton 
X-100 + compleate protease inhibitor). Blood, plasma and corticospinal fluid samples were 
prediluted 1:1 in sample buffer. 10 µl sample and 5 µl antibody dilution (europium cryptate 
and D2 labeled antibodies in 50mM NaH2PO4, 400mM NaF, 0.1% BSA, 0.05% Tween) was 
added to each well to a final dilution of 1.5 ng/well 2B7-europium labeled antibody and 30 
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ng/well MW1-D2-labeled antibody. Plates were incubated at 4°C for 1h. Measurements were 
performed with a Xenon-lamp Envision Reader for 620 and 665 nm wavelengths after 
excitation at 320 nm (time delay 100 µs, window 400 µs, 100 flashes per well). 
 
Data analysis 
The time resolved-FRET readouts are performed at 620 and 665 nm wavelength. The signal 
obtained from the 620 nm wavelength is a huntingtin unspecific signal and results from the 
emission of the europium labeled antibody. It is possible to use the 620 nm signal as a control 
reference signal for possible artifacts caused by scattering, quenching, absorption or general 
turbidity resulting from the analyzed sample. The huntingtin specific signal at 665 nm 
wavelength is caused by the time delayed excitation of the D2 labeled antibody by the 620 nm 
emission of the europium labeled antibody. Therefore, 665/620 nm ratio calculation results in 
an artifact corrected specific determination of the amount of the two antibodies binding in 
close proximity of each other on the huntingtin protein. As the antibodies are present in excess, 
665/620 ratio is a precise reflection of the amount of antigen present in the sample.  
 
Statistical analysis 
Quantification of cellular and mouse values are presented as averages with standard 
deviations. Significances were calculated by students’ t-test. 
 89 
4.4.4 RESULTS 
Time-resolved Förster resonance energy transfer assay for detection of endogenous 
huntingtin 
Aminoterminal fragments of mutant Htt are neurotoxic in vitro and in vivo (Arrasate et al., 
2004; Li et al., 2000; Varma et al., 2007). Mutant Htt toxicity and aggregation are dependent 
on polyQ length, Htt fragment length, and level of mutant Htt expression (Colby et al., 2006; 
King et al., 2008; Machida et al., 2006; Scherzinger et al., 1999; Wang et al., 2005). We 
recently demonstrated the feasibility to measure in one step intracellular mutant Htt using a 
time resolved-FRET assay. In this assay, an antibody pair recognizes a short artificial tag 
fused to a Htt fragment. (Weiss et al. 2008, submitted) (Figure 38).  
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Figure 38: Binding sites of antibodies used in this study to the 573-Htt construct. While 2B7 and MW1 
detect endogenous Htt epitopes, Beta1, 32A7 and 25H10 are specific against the artificial tag added at the C-
terminus (Weiss et al, submitted). Note: as MW1is specific against the polyQ-stretch, increasing polyQ-length 
will result in stronger and increased MW1 binding (represented by the two antibodies displayed in the figure) (Li 
et al., 2007). 
 
With the aim of detecting untagged mutant Htt, it was necessary to use a different antibody 
pair. In order to measure fragments as well as full-length mutant Htt, we used the monoclonal 
antibody 2B7, which binds to the 17 amino acids preceding the polyQ-repeat at the 
aminoterminus of Htt. We selected MW1, a polyQ-specific antibody (Ko et al., 2001) as 
second antibody. The combination of 2B7 and MW1 antibodies resulted in specific detection 
of all Htt-fragments expressed in HN10 cells, including untagged Htt-exon1 (Figure 39A, 
Exon1-Q25 and -Q72). As expected, using other antibody combinations which included one 
or both of the epitopes against the artificial tag failed to detect the untagged Htt-exon1 
constructs (Figure 39A, Exon1-Q25 and -Q72) but readily detected the Htt constructs carrying 
the tags (Figure 39A, 573-Q25 and -Q72). 
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Figure 39: Mutant huntingtin detection in cellular models of Huntington’s disease. A: Time resolved-FRET 
detection of Htt constructs upon inducible expression in neuronal HN10 clones. Specific detection of 573-Htt-
constructs by different antibody combinations. Using antibody combinations that included one of the epitope 
against the artificial tag which is included in the 573-constructs fails to detect untagged exon1 constructs. Using 
antibody combination 2B7 and MW1 both specific against Htt-endogenous epitopes, results in a Htt specific 
signal for all constructs tested, including the untagged exon1 constructs. B: Time resolved-FRET signal for 2B7-
MW1 detection is polyQ-dependent. Lentiviral expression of untagged Htt-constructs with varying polyQ-length 
with a fixed virustiter resulted in equal expression of all the constructs as shown by western blot. Time resolved-
FRET detection showed a clear dependency of the signal strength on the polyQ-length. Loading: 7 ug total 
protein per sample. C: Detection of full length Htt expressed at endogenous levels. A notable and significant 
signal difference was observed for lysates from ES cells expression full-length Htt with 140 polyQ repeats over 
lysates from Htt knock-out ES cells or ES cells expressing full length Htt with the mice wild-type polyQ length 
of 7 glutamines. Loading: 10 ug total protein per sample. D: Detection of full length Htt expressed at endogenous 
levels in neurons in a polyQ-dependent manner. Detection of full-length huntingtin expressed at endogenous, 
neuronal levels is possible as shown by lysates from ES-derived neurons. In addition, as shown for lentiviral 
system, signal strength is polyQ-dependent. Loading: 40 ug protein per sample. (All figures: n=3, stdev, 
*=p<0.05, **=p<0.01, ***=p<0.001). 
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Clone to clone variations may contribute to different expression levels in the HN10 cell lines, 
thereby possibly complicating efforts to compare polyQ-dependent detection sensitivity when 
analyzing wild-type and mutant huntingtin expression from different clones. To circumvent 
this limitation, we opted for a lentiviral approach for expression of untagged Htt-constructs 
with 25 or 72 glutamines in a homogenous population of mouse embryonic stem cells (ESC; 
(Bibel et al., 2004)). A predefined virus titer led to equal expression of the constructs as 
demonstrated by western blot. Signal strength in time resolved-FRET increased with polyQ-
length (Figure 39B). This was expected, since expansion of the polyQ-repeat would increase 
binding of MW1 relative to wild-type Htt (Ko et al., 2001; Li et al., 2007). These data 
demonstrated specific detection of Htt fragments in a polyQ-dependent manner by the 
antibody pair 2B7-MW1. 
For evaluating the use of the time resolved-FRET assay to detect endogenous, full-length Htt, 
we selected ESC with the Htt gene deleted (Htt knock-out as negative control) or modified by 
a polyQ insertion (polyQ knock-in as positive control). A significant signal was obtained in 
samples from the 140Q knock-in ESC when compared to samples from the Htt knock-out 
ESC (Figure 39C). In contrast, we did not observe a signal above background (mock 
condition) when using normal ESC. This is consistent with the fact that normal mouse Htt has 
a polyQ-stretch of only 7 glutamines, evidently too short for recognition by the MW1 
monoclonal (Figure 39C) (Ko et al., 2001). In cell lysates obtained from ESC-derived 
glutamatergic neurons in which varying polyQ-lengths were knocked-in in the endogenous 
Htt gene, neuronal Htt was detected in a polyQ-length dependent manner (Figure 39D). 
Notably, a significant amount of Htt was detected also for 20Q-Htt, a polyQ length 
representing the majority of the normal human alleles. These data demonstrate that our single-
step detection method can be used for rapid, quantitative and polyQ-length dependent 
detection of endogenous Htt protein in neuronal cells. 
 
Detection of soluble mutant Htt in central and peripheral tissues of murine HD models 
and significant changes in soluble brain Htt as a function of disease progression 
The single-step bioassay for Htt was next used to analyze brain homogenates obtained from 4 
and 12 week-old R6/2 mice and aged-matched wild-type mice. R6/2 mice develop an 
aggressive HD-like phenotype because of the ubiquitous expression of mutant Htt exon1 
driven by the human Htt promoter (Mangiarini et al., 1996). Figure 40 summarizes the data 
obtained for the HD mice. Robust signals were observed in all transgenic animals analyzed. 
The mutant Htt specific signal in young, presymptomatic mice was about 25-fold above that 
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measured in wild-type animals (Figure 40A), which is likely to represent the background 
noise as endogenous mouse Htt was not detected in ESC Htt-knock out cells (see above). 
Interestingly, the level of mutant Htt detected in the brain of the older mouse group, which 
have an advanced HD-like phenotype, was about 45% less than that in young R6/2 mice 
(Figure 40A). This decrease in mutant Htt was surprising, as the Htt-aggregate load measured 
in the same brain samples by AGERA increased as a function of age (Weiss et al., 2008) 
(Figure 40A; AGERA blot). One possible explanation for these results was that the time 
resolved-FRET assay using the 2B7-MW1 antibody pair was specific for a mutant Htt fraction 
distinct from mutant Htt aggregates. To further investigate this possibility, we separated by 
ultracentrifugation R6/2 brain homogenates into two fractions, one containing only soluble 
Htt species and one containing Htt aggregates sedimented as an insoluble pellet. Analysis of 
the supernatant and pellet fractions by AGERA demonstrated successful separation of the 
insoluble aggregates into the pellet fraction whereby no aggregates were present in the 
supernatant fractions (Figure 40B, AGERA blot). In contrast, we found that the amount of Htt 
detected by time resolved-FRET was predominantly enriched (most likely in a soluble 
monomeric and oligomeric form) in the supernatant fractions. These data indicated that the 
time resolved-FRET assay was specific for soluble mutant Htt forms. Thus, the decrease in 
the time resolved-FRET signal may indicate recruitment of soluble Htt species into aggregates 
accumulating as a function of age and disease progression, a mechanism also suggested for 
other neurodegenerative disorders such as Alzheimer’s Disease (Sjogren et al., 2002; Strozyk 
et al., 2003).  
We extended our analysis to include muscle and plasma samples from 6 week old as well as 
corticospinal fluid samples from 9 to 12 week old R6/2 or WT mice. We found significant 
detectable amounts of mutant Htt in the R6/2 mice when compared to their normal siblings in 
all tissue samples analyzed, although the signals in the body fluids were significantly lower 
than those detected in cortical extracts (Figure 40C). 
In the context of a bioassay for mutant Htt, the R6/2 mouse model of HD based on the 
expression of a short fragment of Htt may have only a limited value as a model of the human 
situation in which mutated full-length Htt is expressed. As an alternative, we applied the time 
resolved-FRET assay for the analysis of mutant Htt in a knock-in mouse model expressing 
endogenous mouse full-length Htt with a polyQ-stretch of 140 glutamines (Menalled et al., 
2003). Similar to the R6/2 mouse samples, significant amounts of mutant Htt were detected in 
every brain area analyzed as well as in full blood samples (Figure 40D) obtained from the 
polyQ-knock-in mice.  
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Figure 40: Detection of soluble mutant huntingtin in mice HD models. A: Time resolved-FRET signal in 
brains of R6/2 decreases with age. Full-brain homogenates of 4 and 12 week-old wild-type (WT) or R6/2 mice 
were analyzed with time resolved-FRET using the 2B7-K-MW1-D2 antibody combination. The sensitive time 
resolved-FRET detection resulted in a highly significant signal difference between not only WT and R6/2 mice 
(p<0.001) but also between 4 and 12 week-old R6/2 mice (p<0.001). Time resolved-FRET signal in R6/2 brain 
decreased with age (upper graph) whereas the aggregate load in these samples increases with age (lower AGERA 
blot), indicating that the time resolved-FRET method based on 2B7-MW1 does detect a mutant Htt subspecies 
different from insoluble aggregates. B: Time resolved-FRET detects soluble fraction and not insoluble 
aggregates. Ultracentrifugation (1h at 124000g) of four R6/2 full-brain homogenates separated the insoluble Htt 
aggregates from soluble monomeric/oligomeric species. Analysis of supernatant and pellet fractions showed that 
ultracentrifugation successfully separated the insoluble aggregates into the pellet fractions whereas no aggregates 
were detected in the supernatant fractions (lower AGERA blot). In contrast we found that the Htt signal detected 
by time resolved-FRET is found in the supernatant fractions and thus specific for soluble mutant Htt. C: 
Quantification of mutant Htt-exon1 in R6/2 mice. Cortex, muscle and plasma samples from 6 week old R6/2 or 
WT mice showed a significant signal difference between R6/2 and WT in all samples analyzed (n=3, stdev, 
*=p<0.05, **=p<0.01, ***=p<0.001). Analysis of corticospinal fluid from 9 to 12 week old R6/2 mice (n=9) and 
WT mice (n=4) showed a small but highly significant signal difference between R6/2 and WT CSF. D: 
Endogenous full-length mutant Htt detection in Hdh140 mice. Detection in a knock-in mouse model that 
expresses full-length mutant Htt at endogenous levels is possible with the time resolved-FRET method. Highly 
significant quantification was possible in every tissue sample analyzed. (n=3, stdev, *=p<0.05, **=p<0.01, 
***=p<0.001) 
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Sensitive and polyQ-dependent huntingtin detection in human tissue samples 
Next, we analyzed post-mortem cortex tissue from three HD and three control patients. A 
significant signal difference was observed for all HD patients over the healthy controls, 
demonstrating the feasibility of our method for sensitive and polyQ-length dependent 
detection of soluble Htt levels in human tissue (Figure 41A). To our knowledge, this is the 
first time that the specific pool of potentially toxic soluble mutant Htt can be accurately 
quantified in human samples. 
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Figure 41: Sensitive and polyQ-dependent huntingtin detection in human tissue samples. A: PolyQ-
dependent Htt detection in post-mortem human cortex. Analysis of cortex homogenates from three Huntington’s 
Disease and three control patients revealed a polyQ-length dependent signal intensity allowing for clear 
distinction of human tissue from a diseased versus a healthy patient. B: Detection of mutant huntingtin in human 
snap frozen full blood samples. Human full blood samples from five living Huntington’s Disease patients and 
four living control patients were analyzed. A clear distinction of the diseased patients from the healthy patients 
based on the polyQ-length dependent detection of Htt was possible. Averages of technical triplicates with 
standard deviation are shown for each patient.  C-D: Separation of EDTA treated full blood into red blood cells 
and buffy coat fraction revealed polyQ-dependent detection of mutant Htt in erythrocytes and buffy coat cells of 
Huntington’s Disease patients. Average of technical triplicates with standard deviation are shown for each 
patient.  
 
We proceeded to test human full blood, red blood cells (erythrocytes) and human buffy coat 
samples from five living HD and four control patients (Table 2). As in the post-mortem cortex 
tissue analyzed, we were able to identify all five living HD patients based on their increased 
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time resolved-FRET polyQ-Htt-dependent signal in full blood, erythrocytes and buffy coat 
over the signal of the four healthy control patients (Figure 41B-D).   
Patient Sex Age TFC
1 F 42 10
2 F 62 5
3 F 46 10
4 M 50 9
5 F 45 6
6 M 30 13
7 M 23 13
8 M 24 13
9 F 54 13
Healthy control 
patient
Huntington's 
Disease patient
 
Table 2: Patients providing blood samples. The age, sex and total functional capacity (TFC) score (13=normal; 
0=severe disability) for each patient are shown.  
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4.4.5 DISCUSSION 
We have developed a bioassay for determination of soluble mutant Htt and demonstrated its 
use to measure mutant Htt levels in cell lysates, animal and human tissues. The time resolved-
FRET assay is a simple, one-step methodology that requires only small sample volumes. 
Quantitative determination of mutant Htt levels are therefore possible with as little as 5 µl 
human full blood, providing the possibility to determine soluble mutant Htt protein levels 
multiple times over a longer clinical trial period without affecting the patient as obtaining the 
sample is minimally invasive. In addition, the ability to correct for artifacts using the time 
resolved-FRET method allows for a very reliable quantification of mutant Htt even in small 
sample sizes (Imbert et al., 2007).  
To verify the specifity of our detection method for soluble mutant Htt, several experimental 
steps were taken. Importantly, we based our bioassay on a method that has been recently 
described to detect intracellular levels of tagged Htt fragments in a sensitive, robust and 
reliable manner as indicated by a high Z-factor value, a common statistical parameter that 
reflects assay quality in terms of reliability and robustness (Zhang et al., 1999, Weiss et al. 
submitted). By exchanging the detection antibodies of the high-throughput screen to an 
antibody pair that recognizes endogenous Htt epitopes, we were able to show detection of 
untagged Htt fragments in a stable neuronal cell line with inducible expression of tagged Htt. 
In order to specifically detect mutant Htt levels over wild-type Htt, one of the antibodies is 
directed against the polyQ-repeat that is elongated in Huntington’s Disease. We showed that 
the signal intensity directly correlates with the polyQ length in lentiviral infected embryonic 
stem cells as well as in cell lysates obtained from wild-type and polyQ-knock-in embryonic 
stem cells and embryonic stem cell derived neurons. Critically, using knock-out embryonic 
stem cell lysates void of any Htt protein expression, we were able to prove the Htt specificity 
of our signal. As the detection method is polyQ-length dependent, it should be noted that 
while wild-type Htt is not detected in murine cells or tissue due to the WT-polyQ-length of 
only 7 glutamines, human healthy polyQ length normally resides around ~20 glutamines 
(Myers, 2004), a length that is also detected by our method. However, the intensity of this 
healthy Htt derived signal only contributes little to the total signal that is largely comprised of 
mutant polyQ Htt detection with polyQ-length >39 glutamines. 
We proceeded to analyze mouse models of HD and for the first time were able to quantifiably 
determine soluble, non-aggregated mutant Htt levels in various tissue samples of two different 
HD mouse models. Notably, we found that the levels of soluble mutant Htt decrease while the 
amount of insoluble Htt aggregates increase in the brains of aging R6/2 mice. This decrease of 
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an aggregation prone monomeric species upon aging resembles similar findings in Alzheimer 
Disease whereby a decrease in Abeta42 levels is a marker for disease progression (likely to be 
caused by recruitment of soluble Abeta as a function of increased plaque burden).  
Finally, we tested human post-mortem cortex samples as well as full blood and blood-derived 
human samples from living control and HD patients. We were able to clearly distinguish 
between healthy and HD patient samples by the intensity of the signal alone. This quantitative 
detection of soluble Htt in readily available human tissue samples opens up the possibility to 
determine the value of this soluble mutant Htt quantification for use as a potential biomarker 
for HD disease progression. In that regard, it is interesting that the signal measured in buffy 
coat fraction tends to correlate with severity of disease progression as determined by the total 
function capacity score in the analyzed HD patients. This trend was not observed in full blood 
or erythrocytes. However, erythrocytes represent the vast majority of cells found in full blood. 
Erythrocytes display a shorter lifespan than some of the lymphocytes found in the buffy coat 
fraction. In addition, mature erythrocytes differ from other cells as they are void of a nuclei 
and mitochondrial respiration. The difference in time resolved FRET signals could therefore 
be due to the longer lifespan and different cellular characteristics of a lymphocyte 
subpopulation in which effects of mutant huntingtin monomer expression, e.g. huntingtin 
aggregation, can accumulate over time, leading to a decreased signal of soluble mutant 
huntingtin similar to what we observed in R6/2 mice with advanced disease progression. 
Further longitudinal studies with a larger HD patient population could help to elucidate this 
intriguing possibility. In addition, since potential HD therapies could be aimed at influencing 
the soluble mutant Htt pool directly (e.g. RNAi knockdown of mutant huntingtin, compounds 
that alter aggregation, compounds that act on the chaperone system or compounds that act on 
autophagy) the precise quantification of soluble mutant Htt could also find application as a 
marker for treatment success in human clinical trials. 
In summary, our bioassay is a very simple, one-step methodology that requires only small 
sample volumes. In addition, the artifact corrected nature of time resolved-FRET allows for 
very reliable Htt-quantification with a single small sample per subject, making the method 
useful for experiments that are limited by sample numbers or sample volume as it is often 
found in human clinical trials. Because signal specifity of the method depends on the antibody 
pair used, the method could also find further application not only for HD but also for other 
diseases, especially other polyQ-diseases like the spinocerebellar ataxias. 
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5 GENERAL DISCUSSION AND OUTLOOK 
This thesis focused on the development and application of new models, methods and 
therapeutic approaches for the investigation of Huntington’s Disease, a fatal 
neurodegenerative disorder caused by the expression of mutated huntingtin protein (Bates et 
al., 2002). Currently, no cure for this devastating disease exists (Bonelli and Hofmann, 2007). 
To help in elucidating the open questions about the affected cellular mechanism in 
Huntington’s Disease, we developed an inducible neuronal model and established readouts to 
measure the effects of mutant huntingtin expression (Chapter 4.1.). The observed effects on 
cell viability, transcriptional dysregulation and neurite formation are consistent with earlier 
reports (Borrell-Pages et al., 2006; Hodges et al., 2006; Landles and Bates, 2004). We made 
use of our model to develop two new methods for the detection of aggregated and soluble 
mutant huntingtin protein (AGERA method: Chapter 4.2; TR-FRET method: Chapter 4.4). 
Since these methods are specific for huntingtin protein because of the use of anti-huntingtin 
antibodies, these methods can in principle be applied to a variety of other targets of interest by 
using alternative antibodies directed against other proteins.  
The presented results focused solely on the mutated huntingtin protein while leaving the 
question of a potential RNA toxicity in Huntington’s Disease untouched. Understanding the 
potential role of RNA toxicity in disease development is important as numerous nucleotide 
expansion diseases are thought to be caused by pathogenic RNA and not pathogenic protein. 
So far, almost 30 hereditary diseases are known to result from nucleotide repeat expansions 
(Mirkin, 2007; Pearson et al., 2005). Interestingly, nucleotide expansions in exons can only be 
found in approximately 50% of these diseases. In the rest of the known nucleotide expansion 
disorders, elongation of the DNA are found in the 5' or 3' untranslated regions or in introns. 
Consequently, these nucleotide expansions do not result in expression of mutated proteins but 
in transcription of altered RNAs or changed levels of protein expression.  
The mechanisms how RNA with expanded nucleotide repeats can become toxic in these 
diseases are not yet fully understood. Studies in myotonic dystrophy, a disorder caused by 
nucleotide expansion in an untranslated gene region (Brook et al., 1992), showed that 
expanded RNA can form hairpin structures and distinct RNA foci inside the nucleus (Davis et 
al., 1997). These foci seem to sequester proteins like muscleblind-like protein 1 (MBNL1) or 
CUG RNA-binding protein 1 (CUG-BP1) which play a role in alternative RNA splicing 
(Fardaei et al., 2002; Ho et al., 2004; Miller et al., 2000). In good agreement with these in 
vitro observations are studies which show that deregulation of RNA splicing during 
development is a key pathogenic event leading to myotonic dystrophy (Philips et al., 1998). 
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An alternative interesting theory for mRNA toxicity is based on recent studies reporting that 
CNG-triplet mRNA hairpins are not only recognized and cleaved by Dicer protein (Handa et 
al., 2003; Malinina, 2005) but that these resulting (CNG)n fragments seem to have gene 
silencing effects normally reserved for siRNA (Krol et al., 2007). 
In contrast to myotonic dystrophy, Huntington’s Disease and the other eight members of the 
polyglutamine disease family are characterized by an expansion of a CAG repeat in an exon 
coding region leading to a polyglutamine repeat length above a critical threshold in an 
expressed protein. Since the dominating characteristic of all these polyglutamine diseases are 
the visible protein aggregations in the central nervous system, it has been mostly believed that 
these disorders are caused by the mutated proteins and not by the subjacent, altered mRNA.  
Interestingly, a recent study demonstrated that mRNA toxicity contributes significantly to the 
onset and progression of SCA3 and Huntington’s Disease in a drosophila model (Li et al., 
2008). However, several observations speak against toxicity of the huntingtin mRNA. Firstly, 
it has been shown that the amino acid flanking sequences of the polyglutamine repeat have a 
significant influence on the tendency of the protein to aggregate and the overall toxicity 
(Darnell et al., 2007; Dehay and Bertolotti, 2006; Rockabrand et al., 2007). Secondly, 
numerous studies reported that subcellular localization of the mutated protein influences 
disease progression substantially (Benn et al., 2005; Hackam et al., 1999; Martindale et al., 
1998; Perez et al., 1998; Saudou et al., 1998; Wheeler et al., 2000; Yang et al., 2002). In 
addition, posttranslational modifications of the mutant huntingtin protein such as cleavage or 
phosphorylation have been shown to influence the overall disease progression (Graham et al., 
2006; Ratovitski et al., 2007; Warby et al., 2005; Wellington et al., 2002). Notably, expression 
of anti-huntingtin-intrabodies results in specific binding of the huntingtin protein and reduces 
symptoms in cellular and mouse models of Huntington’s Disease (Wang et al., 2008). Finally, 
earlier studies in other drosophila Huntington’s Disease models argue specifically for the 
polyglutamine repeat in the protein itself as the toxic agent (Marsh et al., 2000; McLeod et al., 
2005). All these findings connect the expression, localization and posttranslational 
modifications of the mutated protein directly with disease onset and progression, questioning 
the role of a potential mRNA toxicity in Huntington’s Disease. Nevertheless, a potential 
minor contribution of mRNA toxicity to disease development should not be ruled out and 
further experiments will be needed on this subject. The in the process of this thesis developed 
detection methods for the different conformational subspecies of mutant huntingtin protein 
could complement the already available sensitive detection methods for mRNA in such 
 101 
studies, helping to find a more definitive answer to the possibility of an additional RNA 
toxicity in Huntington’s Disease. 
Because of the above described arguments against a potential RNA toxicity in Huntington’s 
Disease, we were confident that applying our TR-FRET method to screen a small-molecule 
library comprised of 10000 molecules with the aim to identify compounds which lower 
specifically the levels of mutant huntingtin protein will help in approaching an alternative 
therapeutic treatment against Huntington’s Disease (Chapter 4.3). Even though the screen 
identified mostly compounds which influence generic cellular pathways, the specifity of the 
readout for mutant huntingtin and the dynamic response of the assay encouraged us to proceed 
with the analysis of a larger compound library (>1 million compounds). This screen is 
currently in progress and it is expected to be finished by the end of this year. If a verified 
compound hit list can be established, it will be interesting to test the effect of these 
compounds in our readouts for cell viability (Chapter 4.1) and aggregate formation (Chapter 
4.2) in our inducible neuronal model but also other established cellular and animal models of 
Huntington’s Disease (Bates and Hockly, 2003; Sathasivam et al., 1999a).  
A key finding when using the herein described methods was that the levels of soluble and 
aggregated mutant huntingtin seem to display an inverse correlation in aging Huntington’s 
Disease mice (Chapter 4.4). This could be explained by a “sink”-hypothesis-model which 
postulates that the levels of soluble cellular mutant huntingtin protein decrease as they get 
sequestered into a growing number of intracellular mutant huntingtin aggregates associated 
with disease progression. Indeed, a similar observation has been put forward for patients 
suffering of Alzheimer’s Disease, another neurodegenerative disorder characterized by 
misfolded protein fragments prone for aggregation (Sjogren et al., 2002; Strozyk et al., 2003). 
Since we readily detect soluble mutant huntingtin in human samples with our time resolved 
FRET assay and since we observe a correlating trend of advanced human disease progression 
and lower time resolved FRET signals in buffy coat fractions of HD patients (Chapter 4.4), it 
is intriguing to speculate that our finding from the Huntington’s Disease mouse model can be 
translated into humans. If studies with a larger human sample size verify this correlation 
between a decrease of soluble huntingtin and the state of disease progression, our method may 
find use as a diagnostic clinical readout for treatment success of Huntington’s Disease 
therapies and the monitoring of disease progression. Future planned experiments will  
therefore include the analysis of a larger collection of longitudinal patient samples to elucidate 
this intriguing application possibility.  
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